Alkalinization reduces COVID-19 risk: real-time meta-analysis of 14 studies

@CovidAnalysis, September 2026, Version 15 (V1 2023), c19early.org/phmeta.html

Abstract

Significantly lower risk is seen for mortality, progression, recovery, and viral clearance. 11 studies from 10 independent teams in 8 countries show significant benefit.

Meta-analysis using the most serious outcome reported shows 49% [36-59%] lower risk. Results are similar for Randomized Controlled Trials. Early treatment is more effective than late treatment.

Results are very robust—in worst case exclusion sensitivity analysis 13 of 14 studies must be excluded before statistical significance is lost. Emergent results for early vs. late treatment ($p = 0.038$) that match biological mechanisms confirm efficacy.

SARS-CoV-2 requires acidic pH for endosomal entry[1]. Alkalinization of the respiratory mucosa may reduce risk. Studies to date typically use sodium bicarbonate.

No treatment is 100% effective. Protocols combine safe and effective options with individual risk/benefit analysis and monitoring. We also present an analysis focusing on sodium bicarbonate[2]. Alkalinization may affect the natural microbiome, especially with prolonged use. All data and sources to reproduce this analysis are in the appendix.

Shafiee et al. present another meta-analysis for alkalinization, showing significant improvements for mortality and recovery.





ALKALINIZATION FOR COVID-19 — HIGHLIGHTS

Alkalinization reduces risk with very high confidence for mortality, progression, recovery, and in pooled analysis, high confidence for viral clearance, and low confidence for hospitalization and cases.

Emergent results for early vs. late treatment ($p = 0.038$) that match biological mechanisms confirm efficacy.

31st treatment shown effective in November 2021, now with $p = 0.0000000039$ from 14 studies.

Real-time updates and corrections with a consistent protocol for 226 treatments. Outcome specific analysis and combined evidence from all studies including treatment delay, a primary confounding factor.

Introduction

Immediate treatment recommended



Fig. 1. SARS-CoV-2 spike protein fibrin binding leads to thromboinflammation and neuropathology, from[4].

SARS-CoV-2 infection typically starts in the upper respiratory tract, and specifically the nasal respiratory epithelium. Entry via the eyes and gastrointestinal tract is possible, but less common, and entry via other routes is rare. Infection may progress to the lower respiratory tract, other tissues, and the nervous and cardiovascular systems. The primary initial route for entry into the central nervous system is thought to be the olfactory nerve in the nasal cavity[5]. Progression may lead to cytokine storm, pneumonia, ARDS, neurological injury[6-22] and cognitive deficits[9,14], cardiovascular complications[23-29], DNA damage[30-33], organ failure, and death. Even mild untreated infections may result in persistent cognitive deficits[34]—the spike protein binds to fibrin leading to fibrinolysis-resistant blood clots, thromboinflammation, and neuropathology. Systemic treatments may be insufficient to prevent neurological damage[13]. Minimizing replication as early as possible is recommended.

Targeted treatment to the primary location of initial infection



Fig. 2. SARS-CoV-2 virions attached to cilia of nasal epithelial cells, from Chien-Ting Wu [35,36].

Logically, stopping replication in the upper respiratory tract should be simpler and more effective. *Wu et al.*, using an airway organoid model incorporating many *in vivo* aspects, show that SARS-CoV-2 initially attaches to cilia—hair-like structures responsible for moving the mucus layer and where ACE2 is localized in nasal epithelial cells [37]. The mucus layer and the need for ciliary transport slow down infection, providing more time for localized treatments [35,36]. Early or prophylactic nasopharyngeal/oropharyngeal treatment may avoid the consequences of viral replication in other tissues, and avoid the requirement for systemic treatments with greater potential for side effects.

Many treatments are expected to modulate infection

SARS-CoV-2 infection and replication involves the complex interplay of 500+ host and viral proteins and other factors [A,38-45], providing many therapeutic targets for which many existing compounds have known activity. Scientists have predicted that over 12,000 compounds may reduce COVID-19 risk [46], either by directly minimizing infection or replication, by supporting immune system function, or by minimizing secondary complications.

Acidic pH enhances infection, alkalinization may inhibit infection

Kreutzberger et al. showed that SARS-CoV-2 requires acidic pH for fusion. The mean pH of the airway-facing surface of the nasal cavity was 6.6, compatible with fusion, while pH is neutral in other parts of the nasopharyngeal cavity and in the lung [47], suggesting no viral fusion in those locations prior to endocytic uptake. *Liu et al.* found that a more acidic pH significantly increased SARS-CoV-2 pseudovirus infection and cell surface ACE2 levels, mediated by pH-dependent inhibition of actin polymerization. Treatments that increase the pH of respiratory mucosa may inhibit fusion and reduce risk for COVID-19.

Analysis

We analyze all significant controlled studies of alkalinization for COVID-19. Search methods, inclusion criteria, effect extraction criteria (more serious outcomes have priority), all individual study data, PRISMA answers, and statistical methods are detailed in Appendix 1. We present random-effects meta-analysis results for all studies, studies within each treatment stage, individual outcomes, and Randomized Controlled Trials (RCTs).

Treatment timing

Fig. 3 shows stages of possible treatment for COVID-19. Prophylaxis refers to regularly taking medication before becoming sick, in order to prevent or minimize infection. Early treatment refers to treatment immediately or soon after symptoms appear, while late treatment refers to more delayed treatment.

Preclinical Research

3 *in vitro* studies support the efficacy of alkalinization [1,48,49].

Preclinical research is an important part of the development of treatments, however results may be very different in clinical trials. Preclinical results are not used in this paper.

Results

Table 1 summarizes the results for all stages combined, for Randomized Controlled Trials, and for specific outcomes. Table 2 shows results by treatment stage. Fig. 4 shows a timeline of the results in alkalinization studies. Fig. 5 plots individual results by treatment stage. Fig. 6, 7, 8, 9, 10, 11, 12, 13, and 14 show forest plots for random-effects meta-analysis of all studies with pooled effects, mortality results, ICU admission, hospitalization, progression, recovery, cases, viral clearance, and nasopharyngeal/oropharyngeal administration (excluding late treatment).



Fig. 3. Treatment stages.

	Relative Risk	Studies	Patients
All studies	0.51 [0.41-0.64] ****	14	6,320
RCTs	0.57 [0.44-0.74] ****	9	1,140
Mortality	0.54 [0.41-0.72] ****	9	5,892
Hospitalization	0.73 [0.52-1.03]	3	616
Recovery	0.74 [0.69-0.80] ****	3	901
Viral	0.59 [0.36-0.95] *	3	289
RCT mortality	0.75 [0.58-0.97] *	4	712

Table 1. **Random-effects meta-analysis for all stages combined, for Randomized Controlled Trials, and for specific outcomes.** Results show the relative risk with treatment and the 95% confidence interval. * $p<0.05$ *** $p<0.001$ **** $p<0.0001$.

	Early treatment	Late treatment	Prophylaxis
All studies	0.24 [0.12-0.51] ***	0.55 [0.44-0.68] ****	0.55 [0.24-1.22]
RCTs	0.24 [0.12-0.51] ***	0.65 [0.53-0.80] ****	0.55 [0.24-1.22]
Mortality		0.54 [0.41-0.72] ****	
Hospitalization	0.14 [0.01-2.65]	0.75 [0.54-1.04]	
Recovery	0.76 [0.60-0.96] *	0.75 [0.68-0.82] ****	
Viral	0.63 [0.19-2.06]	0.58 [0.34-0.98] *	
RCT mortality		0.75 [0.58-0.97] *	

Table 2. **Random-effects meta-analysis results by treatment stage.** Results show the relative risk with treatment and the 95% confidence interval. * $p<0.05$ *** $p<0.001$ **** $p<0.0001$.



Fig. 4. **Timeline of results in alkalinization studies.** The marked dates indicate the time when efficacy was known with a statistically significant improvement of ≥10% from ≥3 studies for pooled outcomes, one or more specific outcome, pooled outcomes in RCTs, and one or more specific outcome in RCTs. Efficacy based on RCTs only was delayed by 12.0 months, compared to using all studies. Efficacy based on specific outcomes was delayed by 6.2 months, compared to using pooled outcomes. Efficacy based on specific outcomes in RCTs was delayed by 7.5 months, compared to using pooled outcomes in RCTs.



Fig. 5. Scatter plot showing the most serious outcome in all studies, and for studies within each stage. Diamonds shows the results of random-effects meta-analysis.



Fig. 6. **Random-effects meta-analysis for all studies.** This plot shows pooled effects, see the specific outcome analyses for individual outcomes. Analysis validating pooled outcomes for COVID-19 can be found below. Effect extraction is pre-specified, using the most serious outcome reported. For details see the appendix.



Fig. 7. **Random-effects meta-analysis for mortality results.**



Fig. 8. Random-effects meta-analysis for ICU admission.



Fig. 9. Random-effects meta-analysis for hospitalization.



Fig. 10. Random-effects meta-analysis for progression.



Fig. 11. Random-effects meta-analysis for recovery.



Fig. 12. Random-effects meta-analysis for cases.



Fig. 13. Random-effects meta-analysis for viral clearance.



Fig. 14. **Random-effects meta-analysis for nasopharyngeal/oropharyngeal administration (excluding late treatment).** Effect extraction is pre-specified, using the most serious outcome reported, see the appendix for details. Analysis validating pooled outcomes for COVID-19 can be found below.

Randomized Controlled Trials (RCTs)

Fig. 15 shows a comparison of results for RCTs and observational studies. Fig. 16 and 17 show forest plots for random-effects meta-analysis of all Randomized Controlled Trials and RCT mortality results. RCT results are included in Table 1 and Table 2.



Fig. 15. **Results for RCTs and observational studies.**

RCTs have many potential biases

RCTs help to make study groups more similar and can provide a higher level of evidence, however they are subject to many biases[50], and analysis of double-blind RCTs has identified extreme levels of bias[51]. For COVID-19, the overhead may delay treatment, dramatically compromising efficacy; they may encourage monotherapy for simplicity at the cost of efficacy which may rely on combined or synergistic effects; the participants that sign up may not reflect real world usage or the population that benefits most in terms of age, comorbidities, severity of illness, or other factors; standard of care may be compromised and unable to evolve quickly based on emerging research for new diseases; errors may be made in randomization and medication delivery; and investigators may have hidden agendas or vested interests influencing design, operation, analysis, reporting, and the potential for fraud. All of these biases have been observed with COVID-19 RCTs. There is no guarantee that a specific RCT provides a higher level of evidence.

Conflicts of interest for COVID-19 RCTs

RCTs are expensive and many RCTs are funded by pharmaceutical companies or other organizations with conflicts of interest, for example governments that previously denied treatment with the study drug. For COVID-19, this creates an incentive to show efficacy for patented commercial products, and an incentive to show a lack of efficacy for inexpensive treatments. The bias is expected to be significant, for example *Als-Nielsen et al.* analyzed 370 RCTs from Cochrane reviews, showing that trials funded by for-profit organizations were 5 times more likely to recommend the experimental drug compared with those funded by nonprofit organizations. *Bekelman et al.* and *Lundh et al.* show that industry-sponsored studies are more likely to be favorable. For COVID-19, some major philanthropic organizations are largely funded by investments with extreme conflicts of interest for and against specific COVID-19 interventions.

RCTs for novel acute diseases requiring rapid treatment

High quality RCTs for novel acute diseases are more challenging, with increased ethical issues due to the urgency of treatment, increased risk due to enrollment delays, and more difficult design with a rapidly evolving evidence base. For COVID-19, the most common site of initial infection is the upper respiratory tract. Immediate treatment is likely to be most successful and may prevent or slow progression to other parts of the body. For a non-prophylaxis RCT, it makes sense to provide treatment in advance and instruct patients to use it immediately on symptoms, just as some governments have done by providing medication kits in advance. Unfortunately, no RCTs have been done in this way. Every treatment RCT to date involves delayed treatment. Among the 226 treatments we have analyzed, 67% of RCTs involve very late treatment 5+ days after onset. No non-prophylaxis COVID-19 RCTs match the potential real-world use of early treatments. They may more accurately represent results for treatments that require visiting a medical facility, e.g., those requiring intravenous administration.

RCT bias for widely available treatments

RCTs have a bias against finding an effect for interventions that are widely available—patients that believe they need the intervention are more likely to decline participation and take the intervention. RCTs for alkalinization are more likely to enroll low-risk participants that do not need treatment to recover, making the results less applicable to clinical practice. This bias is likely to be greater for widely known treatments, and may be greater when the risk of a serious outcome is overstated. This bias does not apply to the typical pharmaceutical trial of a new drug that is otherwise unavailable.



Fig. 18. For COVID-19, observational study results do not systematically differ from RCTs, RR 0.97 [0.91-1.03] across 226 treatments[55].

Observational studies have been shown to be reliable

Evidence shows that observational studies can also provide reliable results. *Concato et al.* found that well-designed observational studies do not systematically overestimate the magnitude of the effects of treatment compared to RCTs. *Anglemyer et al.* analyzed reviews comparing RCTs to observational studies and found little evidence for significant differences in effect estimates.

We performed a similar analysis across the 226 treatments we cover, showing no significant difference in the results of RCTs compared to observational studies, RR 0.97 [0.91-1.03][58]. Similar results are found for all low-cost treatments, RR 0.98 [0.90-1.06]. High-cost treatments show a non-significant trend towards RCTs showing greater efficacy, RR 0.92 [0.84-1.02]. Details can be found in the supplementary data.

Lee (B) et al. showed that only 14% of the guidelines of the Infectious Diseases Society of America were based on RCTs. Evaluation of studies relies on an understanding of the study and potential biases. Limitations in an RCT can outweigh the benefits, for example excessive dosages, excessive treatment delays, or remote survey bias may have a greater effect on results. Ethical issues may also prevent running RCTs for known effective treatments. For more on issues with RCTs see[60,61].

RCTs may be less reliable

Concato et al. report a paradoxical finding—RCT results had higher variability, and only RCTs were found to sometimes report significant results the opposite of the overall result. The same trend is seen for the most popular (most politicized) COVID-19 treatments—considering all statistically significant results reported in studies, RCTs are slightly more likely to report a result in the opposite direction. In other words, for these COVID-19 treatments and for the topics covered by *Concato et al.*, assuming causality from a single study is more likely to result in an incorrect conclusion for RCTs.

Increased risk of inconsistent results for RCTs suggests higher prevalence of bias, which may arise due to many issues including design bias, conflicts of interest, treatment differences by physicians aware of allocation, attrition bias, ascertainment bias, randomization failures, errors, or fraud.

Using all studies identifies efficacy 8+ months faster (9+ months for low-cost treatments)

Currently, 59 of the treatments we analyze show statistically significant efficacy or harm, defined as ≥10% decreased risk or >0% increased risk from ≥3 studies. Of these, 54% have been confirmed in RCTs, with a mean delay of 7.8 months (62% with 8.7 months delay for low-cost treatments). The remaining treatments either have no RCTs, or the point estimate is consistent.

All studies must be carefully analyzed

Neither observational studies nor RCTs prove causation—any study can be flawed or fraudulent. We need much more, for example a combination of results from many independent teams, detailed understanding of each study, knowledge of conflicts/team reliability, dose-response relationships, delay-response relationships, logical results across outcomes, or details consistent with preclinical expectations.

All studies must be evaluated individually. RCTs for a given medication and disease may be more reliable, however they may also be less reliable. For off-patent medications, very high conflict of interest trials may be more likely to be RCTs, and more likely to be large trials that dominate meta-analyses.



Fig. 16. **Random-effects meta-analysis for all Randomized Controlled Trials.** This plot shows pooled effects, see the specific outcome analyses for individual outcomes. Analysis validating pooled outcomes for COVID-19 can be found below. Effect extraction is pre-specified, using the most serious outcome reported. For details see the appendix.



Fig. 17. **Random-effects meta-analysis for RCT mortality results.**

Application



Fig. 19. Optimal spray angle may increase nasopharyngeal drug delivery 100x for nasal sprays, adapted from *Akash et al.*

In addition to the dosage and frequency of administration, efficacy for nasopharyngeal/oropharyngeal treatments may depend on many other details. For example considering sprays, viscosity, mucoadhesion, sprayability, droplet size[62,63], dispersion[63], and application angle[62] are important.

Akash et al. performed a computational fluid dynamics study of nasal spray administration showing 100x improvement in nasopharyngeal drug delivery using a new spray placement protocol, which involves holding the spay nozzle close to horizontal at the nostril, with a slight tilt towards the cheeks. The study also found the optimal droplet size range for nasopharyngeal deposition was ~7-17μm.

Interaction Matching Biological Mechanisms

With 14 studies for alkalinization, we can analyze interactions between subgroups of studies. A significant interaction that matches the biological mechanisms provides further confirmation of efficacy. Analysis of early vs. late treatment shows a significant interaction, with $p = 0.038$.

This reinforces the reliability of the overall finding that alkalinization reduces risk for COVID-19. If the observed efficacy was due to a systematic bias increasing efficacy in results, we would not expect analysis across studies to find this significant interaction that matches the biological mechanisms.

Media Censorship

Low-cost treatments were subject to bias and censorship during the pandemic. Scientific bias is seen in the design, analysis, presentation, and selective reporting of studies, which often favored negative results. A similar bias is seen in the media coverage for low-cost treatments. While broadly seen, bias was particularly notable for ivermectin and hydroxychloroquine, e.g., Scott Alexander noted that *"if you say anything in favor of ivermectin you will be cast out of civilization and thrown into the circle of social hell reserved for Klan members and 1/6 insurrectionists. All the health officials in the world will shout 'horse dewormer!' at you and compare you to Josef Mengele."*[64].

We analyze media coverage for the 226 treatments we cover using Altmetric[65], which reports the number of ~12,000 tracked news outlets that covered each study[66]. Studies are considered to have received significant media coverage if they were covered by at least 0.5% of the tracked news outlets. Fig. 20, 21, and 22 show the bias toward negative results for low-cost treatments, in contrast to the opposite bias for high-profit treatments. This may result in widespread incorrect perceptions on the relative efficacy of high-profit and low-cost treatments. The impact is significant—increased cost limits the use of high-profit treatments and treatment equity, and high-profit treatments were also more difficult to access, especially for earlier treatment which improves efficacy and minimizes community transmission.

The mainstream media did not cover any of the positive studies for alkalinization.





Fig. 20. Media was more likely to cover negative or inconclusive results for low-cost treatments, and positive results for high-profit treatments.



Fig. 21. Mainstream media was biased against positive results for low-cost treatments.



Fig. 22. In contrast to the results for low-cost treatments, mainstream media was biased towards positive results for high-cost treatments.

A combination of factors may have led to the media's suppression of low-cost treatments:

- Politicization led to a media environment where coverage was often framed to support a political narrative rather than to provide objective scientific information. As Scott Alexander said: *"if you say anything in favor of ivermectin you will be cast out of civilization and thrown into the circle of social hell reserved for Klan members and 1/6 insurrectionists. All the health officials in the world will shout 'horse dewormer!' at you and compare you to Josef Mengele."* There was strong social pressure to discredit low-cost treatments.
- Censorship of information conflicting with selected authorities. For example, individuals and organizations presenting conflicting science were often banned on Twitter and YouTube.
- FDA requires *"no adequate, approved, and available alternatives"* in order to grant an EUA for novel high-profit interventions, creating a strong incentive for authorities to ignore or downplay existing low-cost treatments.
- Regulatory capture biases authorities towards high-profit interventions.
- Authorities ignored most evidence for low-cost treatments, for example the NIH references only 2% of studies in delayed, rarely-updated, biased commentaries with no quantitive analysis.
- Media coverage of science is often not very accurate, e.g., misunderstanding confounding issues. For example the media widely considered the RECOVERY HCQ RCT to be conclusive on efficacy, but very late treatment of late stage patients (mostly on oxygen already) with an excessive toxic dose (shown dangerous in a dose comparison RCT) provides no information on the recommended early/prophylactic treatment. With difficulting in understanding basic confounders like treatment delay and dose, the media may favor deferring to authorities. Many studies for low-cost treatments require greater expertise to analyze. Relatively few journalists have a strong ability to analyze clinical trials and are outnumbered by the rest.
- Substantial funding from pharmaceutical advertising biases editorial decisions towards high-profit interventions.
- PR power - companies/teams with strong PR presence are favored in the media, which correlates with high-profit and high conflict of interest studies.
- The media was very negative in general, inflating risk, fear, and anxieties. A negative bias may improve ratings and revenue, increasing motivation to continue watching coverage. A combination of low-cost treatments greatly reducing risk conflicts with the negative narrative.

Authority Delay

25 low-cost treatments were approved in one or more countries, yet many countries approved no low-cost treatments. The countries that did adopt low-cost treatments analyzed the evidence early and made timely approvals. With few exceptions, authorities did not change their initial views, regardless of how much evidence accumulated showing either efficacy or harm. Why?

The harms of smoking here hidden for 25 years[B]. Authorities did not analyze the data in real-time, failing to act when harm was known. Widespread acknowledgement of harm came only after attempts by two new surgeon generals, along with pressure from health advocates and a new president, and a review of 7,000 studies.

Similarly for COVID-19, most authorities and experts did not proactively analyze data in real-time. This guarantees delayed recognition of efficacy or harm, by which time moral, legal, career, and reputational liabilities strongly disincentivize any admission of error. Claims of no efficacy (for effective treatments) or safety (for harmful treatments) were often made prior to strong data being available. Correction would require admitting to errors that increased mortality, which is unlikely with the same generation of officials.

Analysis of potential treatments was rarely done, and when done these were typically minimal efforts. For example, NIH reviews were highly delayed, cover only a tiny fraction of treatments, reference only 2% of studies for the treatments covered, and include no quantitative analysis. They appear as rarely updated side projects from external panels implicitly tasked with justifying prior failures. As with smoking, the thousands of studies could (and should) have been analyzed and acted on in real-time.

A key structural improvement, applicable to all current and future diseases, is for authorities to implement real-time proactive analysis of clinical evidence. This does not remove all bias, but does make it possible to act on evidence, whereas delayed action may be unlikely due to moral, legal, career, and reputational liabilities.

Heterogeneity

Heterogeneity in COVID-19 studies arises from many factors including:

Treatment delay

The time between infection or the onset of symptoms and treatment may critically affect how well a treatment works. For example an antiviral may be very effective when used early but may not be effective in late stage disease, and may even be harmful. Oseltamivir, for example, is generally only considered effective for influenza when used within 0-36 or 0-48 hours[67,68]. Baloxavir marboxil studies for influenza also show that treatment delay is critical — *Ikematsu et al.* report an 86% reduction in cases for post-exposure prophylaxis, *Hayden et al.* show a 33 hour reduction in the time to alleviation of symptoms for treatment within 24 hours and a reduction of 13 hours for treatment within 24-48 hours, and *Kumar et al.* report only 2.5 hours improvement for inpatient treatment.

Delayed public health acknowledgments

Official acknowledgment of efficacy or harm is often delayed—legal, career, and status risks disincentivize admission of error.

	EVIDENCE	OFFICIAL ACKNOWLEDGMENT	APPROX. DELAY
Citrus Fruit (vitamin C) for Scurvy (effectiveness)	1747: James Lind conducted one of the first-ever controlled clinical trials, proving that oranges and lemons cured scurvy in sailors.	1795: The British Royal Navy finally made a daily ration of lemon juice a standard issue for all its sailors, effectively eliminating the disease.	48 years
Handwashing (lower mortality)	1847: Dr. Ignaz Semmelweis provided conclusive proof that having doctors wash their hands with a chlorine solution before delivering babies reduced maternal mortality rates from over 18% to around 1%.	~1870s: Semmelweis's findings were rejected and he was ridiculed. His work was only validated decades later (after his death).	~20+ years
Helicobacter pylori (bacteria causes ulcers)	1982-1984: Marshall and Warren discovered that Helicobacter pylori bacteria causes ulcers, confirmed via direct exposure. Officials maintained that ulcers were caused by stress and spicy food.	1994: The US NIH released a consensus statement officially recommending antibiotics as the standard treatment for peptic ulcers, overturning decades of acid-suppression therapy.	~12 years
Asbestos (causes asbestosis & cancer)	1924: The *British Medical Journal* published the first case study of a death from "asbestosis." By 1918, U.S. insurance companies had stopped selling life insurance to asbestos workers.	1971 (US): The Occupational Safety and Health Administration (OSHA) was formed and began regulating asbestos as a carcinogen, setting the first federal workplace safety standards for it.	~47 years
Leaded Gasoline (neurotoxicity)	~1924: Dangers of low-level lead exposure were known. Experts like Alice Hamilton warned the U.S. Surgeon General that adding lead to gasoline would cause widespread public poisoning.	1973 (US): The Environmental Protection Agency (EPA) ordered the first phasedown of lead in gasoline, following the Clean Air Act of 1970. A full ban for on-road vehicles took effect in 1996.	~49 years
Harms of Smoking (causes lung cancer)	1939: Franz Müller (Germany) published the first case-control epidemiological study strongly linking tobacco smoking to lung cancer. This was followed by major U.S. & U.K. studies in the 1950s.	1964 (US): The U.S. Surgeon General's report, "Smoking and Health," was released. It was the first U.S. government report to definitively link smoking to lung cancer and heart disease.	25 years

Treatment delay	*Result*
Post-exposure prophylaxis	86% fewer cases [69]
<24 hours	-33 hours symptoms [70]
24-48 hours	-13 hours symptoms [70]
Inpatients	-2.5 hours to improvement [71]

Table 3. **Studies of baloxavir marboxil for influenza show that early treatment is more effective.**

Fig. 23 shows a mixed-effects meta-regression for efficacy as a function of treatment delay in COVID-19 studies from 226 treatments, showing that efficacy declines rapidly with treatment delay. Early treatment is critical for COVID-19.



Fig. 23. **Early treatment is more effective.** Meta-regression showing efficacy as a function of treatment delay in COVID-19 studies from 226 treatments.

Patient demographics

Details of the patient population including age and comorbidities may critically affect how well a treatment works. For example, many COVID-19 studies with relatively young low-comorbidity patients show all patients recovering quickly with or without treatment. In such cases, there is little room for an effective treatment to improve results, for example as in *López-Medina et al.*

SARS-CoV-2 variants

Efficacy may depend critically on the distribution of SARS-CoV-2 variants encountered by patients. Risk varies significantly across variants [73], for example the Gamma variant shows significantly different characteristics [74-77]. Different mechanisms of action may be more or less effective depending on variants, for example the degree to which TMPRSS2 contributes to viral entry can differ across variants [78,79].

Treatment regimen

Effectiveness may depend strongly on the dosage and treatment regimen.

Medication quality

The quality of medications may vary significantly between manufacturers and production batches, which may significantly affect efficacy and safety. *Williams et al.* analyze ivermectin from 11 different sources, showing highly variable antiparasitic efficacy across different manufacturers. *Xu et al.* analyze a treatment from two different manufacturers, showing 9 different impurities, with significantly different concentrations for each manufacturer.

Other treatments

The use of other treatments may significantly affect outcomes, including supplements, other medications, or other interventions such as prone positioning. Treatments may be synergistic [82-106], therefore efficacy may depend strongly on combined treatments.

Effect measured

Across all studies there is a strong association between different outcomes, for example improved recovery is strongly associated with lower mortality. However, efficacy may differ depending on the effect measured, for example a treatment may be more effective against secondary complications and have minimal effect on viral clearance.

Meta-analysis

The distribution of studies will alter the outcome of a meta-analysis. Consider a simplified example where everything is equal except for the treatment delay, and effectiveness decreases to zero or below with increasing delay. If there are many studies using very late treatment, the outcome may be negative, even though early treatment is very effective. All meta-analyses combine heterogeneous studies, varying in population, variants, and potentially all factors above, and therefore may obscure efficacy by including studies where treatment is less effective. Generally, we expect the estimated effect size from meta-analysis to be less than that for the optimal case. Looking at all studies is valuable for providing an overview of all research, important to avoid cherry-picking, and informative when a positive result is found despite combining less-optimal situations. However, the resulting estimate does not apply to specific cases such as early treatment in high-risk populations. While we present results for all studies, we also present treatment time and individual outcome analyses, which may be more informative for specific use cases.

Pooled Effects

Pooled effects are no longer required to show efficacy as of May 2022

This section validates the use of pooled effects for COVID-19, which enables earlier detection of efficacy, however pooled effects are no longer required for alkalinization as of May 2022. Efficacy is now known based on specific outcomes for all studies and when restricted to RCTs. Efficacy based on specific outcomes was delayed by 6.2 months compared to using pooled outcomes. Efficacy based on specific outcomes in RCTs was delayed by 7.5 months compared to using pooled outcomes in RCTs.

Combining studies is required

For COVID-19, delay in clinical results translates into additional death and morbidity, as well as additional economic and societal damage. Combining the results of studies reporting different outcomes is required. There may be no mortality in a trial with low-risk patients, however a reduction in severity or improved viral clearance may translate into lower mortality in a high-risk population. Different studies may report lower severity, improved recovery, and lower mortality, and the significance may be very high when combining the results. *"The studies reported different outcomes"* is not a good reason for disregarding results. Pooling the results of studies reporting different outcomes allows us to use more of the available information. Logically we should, and do, use additional information when evaluating treatments—for example dose-response and treatment delay-response relationships provide additional evidence of efficacy that is considered when reviewing the evidence for a treatment.

Specific outcome and pooled analyses

We present both specific outcome and pooled analyses. In order to combine the results of studies reporting different outcomes we use the most serious outcome reported in each study, based on the thesis that improvement in the most serious outcome provides comparable measures of efficacy for a treatment. A critical advantage of this approach is simplicity and transparency. There are many other ways to combine evidence for different outcomes, along with additional evidence such as dose-response relationships, however these increase complexity.

Ethical and practical issues limit high-risk trials

Trials with high-risk patients may be restricted due to ethics for treatments that are known or expected to be effective, and they increase difficulty for recruiting. Using less severe outcomes as a proxy for more serious outcomes allows faster and safer collection of evidence.

Validating pooled outcome analysis for COVID-19

For many COVID-19 treatments, a reduction in mortality logically follows from a reduction in hospitalization, which follows from a reduction in symptomatic cases, which follows from a reduction in PCR positivity. We can directly test this for COVID-19.

Analysis of the the association between different outcomes across studies from all 226 treatments we cover confirms the validity of pooled outcome analysis for COVID-19. Fig. 24 shows that lower hospitalization is very strongly associated with lower mortality ($p < 0.0000000001$). Similarly, Fig. 25 shows that improved recovery is very strongly associated with lower mortality ($p < 0.0000000001$). Considering the extremes, *Singh et al.* show an association between viral clearance and hospitalization or death, with $p = 0.003$ after excluding one large outlier from a mutagenic treatment, and based on 44 RCTs including 52,384 patients. Fig. 26 shows that improved viral clearance is strongly associated with fewer serious outcomes. The association is very similar to *Singh et al.*, with higher confidence due to the larger number of studies. As with *Singh et al.*, the confidence increases when excluding the outlier treatment, from $p = 0.0000000074$ to $p = 0.00000000015$.



Fig. 24. Lower hospitalization is associated with lower mortality, supporting pooled outcome analysis.



Fig. 25. Improved recovery is associated with lower mortality, supporting pooled outcome analysis.



Fig. 24. Improved viral clearance is associated with fewer serious outcomes, supporting pooled outcome analysis.

Pooled outcomes identify efficacy 5 months faster (7 months for RCTs)

Currently, 59 of the treatments we analyze show statistically significant efficacy or harm, defined as ≥10% decreased risk or >0% increased risk from ≥3 studies. 85% of these have been confirmed with one or more specific outcomes, with a mean delay of 4.6 months. When restricting to RCTs only, 53% of treatments showing statistically significant efficacy/harm with pooled effects have been confirmed with one or more specific outcomes, with a mean delay of 7.5 months. Fig. 27 shows when treatments were found effective during the pandemic. Pooled outcomes often resulted in earlier detection of efficacy.



Fig. 27. **The time when studies showed that treatments were effective, defined as statistically significant improvement of ≥10% from ≥3 studies.** Pooled results typically show efficacy earlier than specific outcome results. Results from all studies often shows efficacy much earlier than when restricting to RCTs. Results reflect conditions as used in trials to date, these depend on the population treated, treatment delay, and treatment regimen.

Limitations

Pooled analysis could hide efficacy, for example a treatment that is beneficial for late stage patients but has no effect on viral clearance may show no efficacy if most studies only examine viral clearance. In practice, it is rare for a non-antiviral treatment to report viral clearance and to not report clinical outcomes; and in practice other sources of heterogeneity such as differences in treatment delay are more likely to hide efficacy.

Summary

Analysis validates the use of pooled effects and shows significantly faster detection of efficacy on average. However, as with all meta-analyses, it is important to review the different studies included. We also present individual outcome analyses, which may be more informative for specific use cases.

Polytherapy

There are many complementary mechanisms of action for COVID-19 treatments, with over 500 therapeutic targets[108]. Studies show complementary

and synergistic effects with polytherapy [82-106]. For example, Jitobaom et al. [83] shows >10x reduction in IC_{50} with ivermectin and niclosamide, an RCT by Said et al. [90] showed the combination of nigella sativa and vitamin D was more effective than either alone, and an RCT by Wannigama et al. [109] showed improved results with fluvoxamine combined with additional treatments, compared to fluvoxamine alone.

SARS-CoV-2 can rapidly acquire mutations altering infectivity, disease severity, and drug resistance even without selective pressure [110-117]. Antigenic drift can undermine more variant-specific treatments like monoclonal antibodies and more specific antivirals. Treatment with targeted antivirals may select for escape mutations [118]. The efficacy of treatments varies depending on cell type [119] due to differences in viral receptor expression, drug distribution and metabolism, and cell-specific mechanisms. Efficacy may also vary based on genetic variants [120-130].

Variable efficacy across variants, cell types, tissues, and host genetics, along with the complementary and synergistic actions of different treatments, all point to greater efficacy with polytherapy. In many studies, the standard of care given to all patients includes other treatments—efficacy seen in these trials may rely in part on synergistic effects. Less variant specific treatments and polytherapy targeting multiple viral and host proteins may be more effective. Meta-analysis of all early treatment trials shows 71% [60-79%] lower risk for studies using combined treatments, compared to 27% [24-30%] for single treatments.



While not reaching statistical significance, alkalinization studies using polytherapy also show greater efficacy than monotherapy studies.



Combined treatment is more effective

c19early.org

SARS-CoV-2 involves the complex interplay of 500+ host and viral proteins and factors, providing many therapeutic targets. Many compounds have antiviral activity for SARS-CoV-2, with many different mechanisms including blocking attachment, entry, and replication. Combinations of treatments, with careful attention to potential side effects, allows improved efficacy via complementary and synergistic mechanisms.

Tissue and cell coverage	Different compounds have different tissue penetration profiles and efficacy across cell types
Variant coverage	Compounds with different viral resistance profiles
Intra/extracellular	Disabling and removing intracellular and extracellular viral particles
Resistance	Minimizing persistence and emergence of resistant variants
Genetics	Robustness against individual variations in efficacy based on genetics
Lower doses	Potentially lower doses of individual agents, reducing toxicity
Viral and host-directed	Antivirals targeting viral and host proteins
Immune system function	Supporting or enhancing natural immune system function
Disease phases	Addressing multiple disease phases (viral replication, inflammation, secondary complications)

Discussion

Nasopharyngeal/oropharyngeal administration

Studies to date use a variety of administration methods to the respiratory tract, including nasal and oral sprays, nasal irrigation, oral rinses, and inhalation. Table 4 shows the relative efficacy for nasal, oral, and combined administration. Combined administration shows the best results, and nasal administration is more effective than oral. Precise efficacy depends on the details of administration, e.g., mucoadhesion and sprayability for sprays.

Combined nasal and oral administration is most effective

Across all nasopharyngeal/oropharyngeal treatments we cover, combined nasal and oral administration shows the highest efficacy, followed by nasal administration, with oral administration alone showing the lowest efficacy.

ADMINISTRATION	IMPROVEMENT	STUDIES
Nasal & oral	88% [72-95%]	10
Nasal spray/rinse	59% [50-66%]	21
Oral spray/rinse	38% [25-49%]	11

Table 4. Respiratory tract administration efficacy. Relative efficacy of nasal, oral, and combined nasal/oral administration for treatments administered directly to the respiratory tract. Results show random-effects meta-analysis for the most serious outcome reported for all prophylaxis and early treatment studies.

Nasopharyngeal/oropharyngeal treatment mechanisms of action

Nasopharyngeal/oropharyngeal treatments work via different methods. Some are drugs with other primary uses and have a greater potential for side effects and drug interactions, for example azelastine and chlorpheniramine are antihistamines. Table 5 summarizes the primary classes of mechanisms of action, and Table 6 shows mechanisms of action for specific treatments.

Nasal/oral sprays and rinses—primary mechanisms

Primary mechanisms of action for nasopharyngeal/oropharyngeal sprays and rinses. Note: sequenced application is possible to maximize efficacy—for example, using a virucidal spray/wash first (to clean), followed by a barrier spray (to protect), with a 5-10 minute drying window in between.

Virucidal action	Chemically inactivating or destroying the structure of viral particles
Blocking attachment	Binding to the virus or host cells to prevent viral attachment to host cells
Physical barrier	Forming a physical layer over the nasal mucosa preventing viral access to host cells
Physical removal	Mechanical washout/flushing of viral particles and mucus (e.g., large volume irrigation)
Mucociliary clearance	Stimulating the natural beating of nasal cilia to accelerate the clearing of trapped pathogens

Table 5. Primary classes for mechanisms of action for nasopharyngeal/oropharyngeal treatments.

Impact on the microbiome

Nasopharyngeal/oropharyngeal treatments may not be highly selective. In addition to inhibiting or disabling SARS-CoV-2, they may also be harmful to beneficial microbes, disrupting the natural microbiome in the oral cavity and nasal passages that have important protective and metabolic roles [142,143]. This may be especially important for prolonged use or overuse. Table 7 summarizes the potential for common nasopharyngeal/oropharyngeal treatments to affect the natural microbiome.

Nasal/oral sprays and rinses may affect the microbiome

Nasopharyngeal/oropharyngeal treatments may significantly alter the microbiome. These effects may be more important with longer-term prophylaxis.

TREATMENT	MICROBIOME DISRUPTION POTENTIAL	NOTES
Iota-carrageenan [137]	Low	Primarily antiviral, however extended use may mildly affect the microbiome
Nitric Oxide [139]	Low to moderate	More selective towards pathogens, however excessive concentrations or prolonged use may disrupt the balance of bacteria
Alkalinization	Moderate	Increases pH, negatively impacting beneficial microbes that thrive in a slightly acidic environment
Cetylpyridinium Chloride [132]	Moderate	Quaternary ammonium broad-spectrum antiseptic that can disrupt beneficial and harmful bacteria
Phthalocyanine [140]	Moderate to high	Photodynamic compound with antimicrobial activity, likely to affect the microbiome
Chlorhexidine [133]	High	Potent antiseptic with broad activity, significantly disrupts the microbiome
Hydrogen Peroxide [135]	High	Strong oxidizer, harming both beneficial and harmful microbes
Povidone-Iodine [141]	High	Potent broad-spectrum antiseptic harmful to beneficial microbes

Table 7. Potential effect of nasopharyngeal/oropharyngeal treatments on the microbiome.

Potential increased risk based on diet

Consuming acidic foods and beverages may temporarily lower salivary pH [144], which could theoretically create a more favorable environment for SARS-CoV-2 infection. While initial infection typically starts in the nasal cavity, lower pH may

Nasal/oral sprays and rinses—mechanisms of action

Nasopharyngeal/oropharyngeal treatments have many different mechanisms of action. Specific treatments may have significant systemic effects or significantly alter the microbiome.

TREATMENT	MECHANISMS	NOTES
Azelastine [131]	Antiviral: inhibits interaction between spike protein and ACE2 Antiviral: potential inhibition of viral protease (Mpro) Other: H1-receptor antagonist (antihistamine) Other: mast cell stabilizer	Antihistamine. Designed to affect human receptors. Risks include dysgeusia, drowsiness, and nasal burning.
Cetylpyridinium Chloride [132]	Virucidal: disrupts viral lipid envelope Antiseptic: quaternary ammonium compound	Chemical virucide. Common in mouthwashes. Can cause temporary staining of teeth or tongue irritation if used frequently.
Chlorhexidine [133]	Virucidal: disrupts viral lipid membranes Antiseptic: cationic polybiguanide	Chemical virucide. May cause tooth staining and altered taste.
Chlorpheniramine [134]	Antiviral: binds to viral spike protein to block entry Antiviral: high affinity for viral transport proteins Other: H1-receptor antagonist (1st generation antihistamine) Other: anticholinergic activity	Antihistamine. Stronger systemic risks than azelastine. Known to cause significant sedation/drowsiness and cognitive impairment.
Hydrogen Peroxide [135]	Virucidal: oxidizing agent that destroys viral parts Other: tissue debridement	Chemical virucide. Can be toxic to healthy tissue if concentration is too high (>1%). Long-term safety on nasal mucosa is debated.
Inhaled Heparin [136]	Antiviral: acts as a decoy receptor (mimics heparan sulfate) Antiviral: anti-inflammatory effects on lung tissue Other: Anticoagulant	Anticoagulant. Use requires caution regarding bleeding risks.
Iota-carrageenan [137]	Barrier: forms a viscous physical layer on mucosa Trap: electrostatistically traps virus particles (mimics cell surface)	Physical barrier. High safety profile for daily use.
NaCl [138]	Cleaning: physically washes away viral particles Support: moisturizes mucosa to support natural immune barrier	Physical wash. High degree of safety, reduces viral load via physical removal.
Nitric Oxide [139]	Virucidal: physically damages viral structure via nitrosylation Other: vasodilator (relaxes blood vessels) in systemic use	Virucide/drug hybrid. In nasal spray form, it acts primarily as a topical disinfectant. Rapidly cleared, so systemic vasodilation risks are low but present.
Phthalocyanine [140]	Virucidal: generates reactive oxygen species (ROS) when exposed to light to kill virus Other: photosensitizer	Chemical virucide. A synthetic compound often used in photodynamic therapy. Works by creating an oxidative environment hostile to the virus.
Povidone-Iodine [141]	Virucidal: oxidizes viral proteins and destabilizes membrane structures Antiseptic: broad-spectrum bacterial/fungal killer	Chemical virucide. Highly effective but risk of thyroid absorption with chronic use. Can be irritating to mucous membranes.
Sodium Bicarbonate [2]	Environment: raises pH to inhibit viral fusion Cleaning: improves mucociliary clearance (washing)	Physical/chemical environment. Changes the environment rather than attacking the virus directly. High degree of safety.

Table 6. Mechanisms of action for nasopharyngeal/oropharyngeal treatments.

facilitate infection in the throat and further progression (changes in nasal cavity pH are also possible, for example via acidic aerosols from carbonated beverages). Other factors that could lower the pH in the respiratory tract include gastroesophageal reflux disease - certain foods and drinks may relax the lower esophageal sphincter, allowing stomach acid to flow back into the esophagus and potentially into the respiratory tract; aspiration - consuming liquids or foods with a low pH can lead to aspiration, where the contents are accidentally inhaled into the lungs, causing irritation and lowering the pH in the respiratory

tract; high sugar diets - consuming excessive amounts of sugar may promote the growth of bacteria in the mouth and throat, which can produce acid and lower the pH in the respiratory tract; and dehydration - not drinking enough water can lead to a decrease in saliva production, which plays a role in neutralizing acid in the mouth and throat, and therefore may result in a lower pH in the respiratory tract. Foods and beverages that can directly lower the pH of the throat include: citrus fruits and juices: lemons, limes, oranges, grapefruits, and their juices have a low pH (2.0-3.0) due to their high citric acid content; carbonated beverages: carbonated drinks have a pH range of 2.0-4.0 due to the presence of carbonic acid; vinegar and vinegar-based dressings: vinegar has a pH of around 2.5-3.0 due to its acetic acid content; tomatoes and tomato-based products: tomatoes, tomato juice, and tomato sauce have a pH range of 4.0-4.5; coffee and tea: while the pH of coffee and tea can vary, they are generally acidic, with pH values ranging from 4.5-6.0; alcoholic beverages: most alcoholic drinks have a pH below 7.0, with wine having a pH of 3.0-3.5 and beer having a pH of 4.0-5.0. When these acidic substances come into contact with the throat, they can temporarily lower the pH. The body has mechanisms to help neutralize the acid and restore the pH balance, such as saliva production and the buffering capacity of the throat's mucous membranes. Frequent exposure to highly acidic substances or having conditions like acid reflux can lead to more persistent changes in the throat's pH.

Studies have not specifically looked at COVID-19 risk based on changes in the respiratory tract pH with different diets, however the benefits of nasopharyngeal/oropharyngeal alkalinization seen here match the expected increased risk with lower pH, and suggest caution with consumption of food and beverages that lowers pH while waiting for the results of controlled clinical studies.

Publication bias

Publishing is often biased towards positive results, however evidence suggests that there may be a negative bias for inexpensive treatments for COVID-19. Both negative and positive results are very important for COVID-19, media in many countries prioritizes negative results for inexpensive treatments (inverting the typical incentive for scientists that value media recognition), and there are many reports of difficulty publishing positive results [145-148]. For alkalinization, there is currently not enough data to evaluate publication bias with high confidence.

One method to evaluate bias is to compare prospective vs. retrospective studies. Prospective studies are more likely to be published regardless of the result, while retrospective studies are more likely to exhibit bias. For example, researchers may perform preliminary analysis with minimal effort and the results may influence their decision to continue. Retrospective studies also provide more opportunities for the specifics of data extraction and adjustments to influence results.

Fig. 28 shows a scatter plot of results for prospective and retrospective studies. 100% of retrospective studies report a statistically significant positive effect for one or more outcomes, compared to 73% of prospective studies, consistent with a bias toward publishing positive results. The median effect size for retrospective studies is 49% improvement, compared to 64% for prospective studies, suggesting a potential bias towards publishing results showing lower efficacy.



Fig. 28. Prospective vs. retrospective studies. The diamonds show the results of random-effects meta-analysis.

Late treatment bias

Studies for alkalinization were mostly late treatment studies, in contrast with typical high-profit drugs that were more likely to be tested with early treatment.



Fig. 29. Early treatment was more common for high-profit drugs.

Funnel plot analysis

Funnel plots have traditionally been used for analyzing publication bias. This is invalid for COVID-19 acute treatment trials — the underlying assumptions are invalid, which we can demonstrate with a simple example. Consider a set of hypothetical perfect trials with no bias. Fig. 30 plot A shows a funnel plot for a simulation of 80 perfect trials, with random group sizes, and each patient's outcome randomly sampled (10% control event probability, and a 30% effect size for treatment). Analysis shows no asymmetry ($p > 0.05$). In plot B, we add a single typical variation in COVID-19 treatment trials — treatment delay. Consider that efficacy varies from 90% for treatment within 24 hours, reducing to 10% when treatment is delayed 3 days. In plot B, each trial's treatment delay is randomly selected. Analysis now shows highly significant asymmetry, $p < 0.0001$, with six variants of Egger's test all showing $p < 0.05$ [149-156]. Note that these tests fail even though treatment delay is uniformly distributed. In reality treatment delay is more complex — each trial has a different distribution of delays across patients, and the distribution across trials may be biased (e.g., late treatment trials may be more common). Similarly, many other variations in trials may produce asymmetry, including dose, administration, duration of treatment, differences in SOC, comorbidities, age, variants, and bias in design, implementation, analysis, and reporting.



Fig. 30. Example funnel plot analysis for simulated perfect trials.

Conflicts of interest

Pharmaceutical drug trials often have conflicts of interest whereby sponsors or trial staff have a financial interest in the outcome being positive. Alkalinization for COVID-19 lacks this because it is off-patent, has multiple manufacturers, and is very low cost. In contrast, most COVID-19 alkalinization trials have been run by physicians on the front lines with the primary goal of finding the best methods to save human lives and minimize the collateral damage caused by COVID-19. While pharmaceutical companies are careful to run trials under optimal conditions (for example, restricting patients to those most likely to benefit, only including patients that can be treated soon after onset when necessary, and ensuring accurate dosing), not all alkalinization trials represent the optimal conditions for efficacy.

Limitations

Summary statistics from meta-analysis necessarily lose information. As with all meta-analyses, studies are heterogeneous, with differences in treatment delay, treatment regimen, patient demographics, variants, conflicts of interest, standard of care, and other factors. We provide analyses for specific outcomes and by treatment delay, and we aim to identify key characteristics in the forest plots and summaries. Results should be viewed in the context of study characteristics.

Some analyses classify treatment based on early or late administration, as done here, while others distinguish between mild, moderate, and severe cases. Viral load does not indicate degree of symptoms — for example patients may have a high viral load while being asymptomatic. With regard to treatments that have antiviral properties, timing of treatment is critical — late administration may be less helpful regardless of severity.

Details of treatment delay per patient is often not available. For example, a study may treat 90% of patients relatively early, but the events driving the outcome may come from 10% of patients treated very late. Our 5 day cutoff for early treatment may be too conservative, 5 days may be too late in many cases.

Comparison across treatments is confounded by differences in the studies performed, for example dose, variants, and conflicts of interest. Trials with conflicts of interest may use designs better suited to the preferred outcome.

In some cases, the most serious outcome has very few events, resulting in lower confidence results being used in pooled analysis, however the method is simpler and more transparent. This is less critical as the number of studies increases. Restriction to outcomes with sufficient power may be beneficial in pooled analysis and improve accuracy when there are few studies, however we maintain our pre-specified method to avoid any retrospective changes.

Studies show that combinations of treatments can be highly synergistic and may result in many times greater efficacy than individual treatments alone [82-106]. Therefore standard of care may be critical and benefits may diminish or disappear if standard of care does not include certain treatments.

This real-time analysis is constantly updated based on submissions. Accuracy benefits from widespread review and submission of updates and corrections from reviewers. Less popular treatments may receive fewer reviews.

No treatment or intervention is 100% available and effective for all current and future variants. Efficacy may vary significantly with different variants and within different populations. All treatments have potential side effects. Propensity to experience side effects may be predicted in advance by qualified physicians. We do not provide medical advice. Before taking any medication, consult a qualified physician who can compare all options, provide personalized advice, and provide details of risks and benefits based on individual medical history and situations.

Notes

3 of 14 studies combine treatments. The results of alkalinization alone may differ. None of the RCTs use combined treatment. Currently all studies are peer-reviewed. *Shafiee et al.* present another meta-analysis for alkalinization, showing significant improvements for mortality and recovery.

Reviews

Multiple reviews cover alkalinization for COVID-19, presenting additional background on mechanisms and related results, including [157-159].

Perspective

Results compared with other treatments

SARS-CoV-2 infection and replication involves a complex interplay of 500+ host and viral proteins and other factors [38-45], providing many therapeutic targets. Over 12,000 compounds have been predicted to reduce COVID-19 risk [46], either by directly minimizing infection or replication, by supporting immune system function, or by minimizing secondary complications. Fig. 31 shows an overview of the results for alkalinization in the context of multiple COVID-19 treatments, and Fig. 32 shows a plot of efficacy vs. cost for COVID-19 treatments.



Fig. 31. **Scatter plot showing results within the context of multiple COVID-19 treatments.** Diamonds shows the results of random-effects meta-analysis. 0.5% of 12,000+ proposed treatments show efficacy [160].



Fig. 32. **Efficacy vs. cost for COVID-19 treatments.**

Conclusion

SARS-CoV-2 infection typically starts in the upper respiratory tract. Progression may lead to cytokine storm, pneumonia, ARDS, neurological issues, organ failure, and death. Stopping replication in the upper respiratory tract, via early or prophylactic nasopharyngeal/oropharyngeal treatment, can avoid the conse-

quences of progression to other tissues, and avoid the requirement for systemic treatments with greater potential for side effects.

Studies to date show that alkalinization is an effective treatment for COVID-19. Significantly lower risk is seen for mortality, progression, recovery, and viral clearance. 11 studies from 10 independent teams in 8 countries show significant benefit. Meta-analysis using the most serious outcome reported shows 49% [36-59%] lower risk. Results are similar for Randomized Controlled Trials. Early treatment is more effective than late treatment.

Results are very robust—in worst case exclusion sensitivity analysis 13 of 14 studies must be excluded before statistical significance is lost. Emergent results for early vs. late treatment ($p = 0.038$) that match biological mechanisms confirm efficacy.

SARS-CoV-2 requires acidic pH for endosomal entry [1]. Alkalinization of the respiratory mucosa may reduce risk. Studies to date typically use sodium bicarbonate.

Shafiee et al. present another meta-analysis for alkalinization, showing significant improvements for mortality and recovery.

We also present an analysis focusing on sodium bicarbonate [2]. Alkalinization may affect the natural microbiome, especially with prolonged use.

Contact. Contact us on X at @CovidAnalysis.

Funding. We have received no funding or compensation in any form, and do not accept donations. This is entirely volunteer work.

Conflicts of interest. We have no conflicts of interest. We have no affiliation with any pharmaceutical companies, supplement companies, governments, political parties, or advocacy organizations.

Disclaimer. We do not provide medical advice. No treatment is 100% effective, and all may have side effects. Protocols combine multiple treatments. Consult a qualified physician for personalized risk/benefit analysis.

AI. We use AI models (Gemini, Grok, Claude, and ChatGPT) tasked with functioning as additional peer-reviewers to check for errors, suggest improvements, and review spelling and grammar. Any corrections are manually verified. Our preference for em dashes is independent of AI.

Updates. Our COVID-19 meta-analyses involve the extraction of over 227,000 datapoints from thousands of papers for 226 treatments. We thank the thousands of scientists, physicians, and other contributors that have provided updates, suggestions, feedback, and corrections. These are all welcome and can be submitted at https://c19early.org/phmeta.html.

Dedication. This work is dedicated to top evidence-based physicians that worked tirelessly to analyze evidence and greatly reduce mortality and morbidity during the pandemic. In alphabetical order: Dr. Thomas J. Borody, Dr. Mary Talley Bowden, Dr. Flavio Cadegiani, Dr. Shankara Chetty, Dr. Ryan Cole, Dr. George Fareed, Dr. Sabine Hazan, Dr. Pierre Kory, Dr. Tess Lawrie, Dr. Robert Malone, Dr. Paul Marik, Dr. Peter McCullough, Dr. Didier Raoult, Dr. Harvey Risch, Dr. Jackie Stone, Dr. Brian Tyson, Dr. Joseph Varon, and Dr. Vladimir Zelenko.

Study Notes

Calonico



Retrospective 5,146 hospitalized COVID-19 patients in Argentina, showing lower mortality associated with nebulized ibuprofen (NaIHS) treatment. Doubly robust inverse probability weighting estimators were used to control for confounding. Authors emphasize the need for randomized controlled trials.

The treatment appears to be the same as detailed in [161], which reports a pH of 8.5. *Kreutzberger et al.* showed that SARS-CoV-2 requires an acidic pH (between 6.2-6.8) for membrane fusion and cell entry, even when the viral spike protein is primed by proteases like TMPRSS2. Efficacy seen here may be more due to alkalinization, which shows more consistent higher efficacy than ibuprofen in studies to date.

de Gabory



RCT 355 adults with COVID-19 or other upper respiratory tract infections (URTIs). For COVID-19 patients there was lower progression and faster symptom

resolution with alkaline seawater nasal wash (pH ~8) 4 times daily for 21 days. There was significantly lower transmission for patients with the delta variant and for patients with high viral load. The seawater nasal wash was safe and well-tolerated.

Delić



RCT mechanically ventilated patients in Croatia, 42 treated with sodium bicarbonate inhalation, and 52 control patients, showing no significant difference in mortality with treatment. Treated patients showed a lower incidence of gram-positive or MRSA-caused ventilator-associated pneumonia. ICU mortality results are from [162].

El-Badrawy



RCT 546 patients showing significantly faster recovery and lower mortality with sodium bicarbonate (inhaled and nasal drops). The reduction in mortality is only statistically significant when excluding baseline critical cases. Authors hypothesize that treatment raises endosomal pH, potentially preventing SARS-CoV-2 attachment and entry into host cells.

Inhalation of nebulized sodium bicarbonate 8.4% (5ml every 4h) 7:00am to 23:00pm every day for 30 days together with 8.4% nasal drops 4 times daily (three drops for each nostril).

El-Badrawy



Prospective study of 182 COVID-19 pneumonia patients, 127 treated with sodium bicarbonate inhalation and nasal drops, showing significantly faster recovery and improved CT scores with treatment.

Authors note that contacts of index cases also received sodium bicarbonate treatment, with none reporting COVID-19.

Inhalation of nebulized sodium bicarbonate 8.4% (5ml every 4h) 7:00am to 23:00pm every day for 30 days together with 8.4% nasal drops 4 times daily (three drops for each nostril).

Kalayan



Retrospective 99 COVID-19 patients in Argentina showing significantly lower mortality with inhaled alkaline hypertonic ibuprofen (AHI) treatment. The treatment has a pH of 8.5. 3 times daily for 7-10 days.

Karami



RCT 116 healthcare workers comparing 0.2% chlorhexidine mouthwash (n=36), 7.5% sodium bicarbonate mouthwash (n=40), and placebo (n=40) twice daily for 2 weeks, with symptoms followed for 4 weeks. There were lower symtoms and cases in both treatment groups, with statistical significance for chlorhexidine only. The treatments were stopped after two weeks, results may be better with continued use, more frequent use, and with the addition of nasal use.

Lumlertgul



Early terminated RCT 16 critically ill COVID-19 patients showing no significant difference in AKI development or mortality with alkalinization using intravenous sodium bicarbonate. The intervention group achieved higher urine pH (75% vs 37.5% reached pH ≥ 7.5), but AKI incidence (37.5% vs 62.5%) and 60-day mortality (12.5% vs 37.5%) were not statistically different. Recruitment stopped early due to declining COVID-19 ICU admissions, limiting sample size.

Mody



RCT 60 hospitalized patients in India, showing significantly greater clinical improvement with inhaled sodium bicarbonate.

Nasal and oral inhalation of nebulized 50ml 8.4% sodium bicarbonate for 5 minutes twice daily for 5 days.

Pantazopoulos



RCT 56 severe COVID-19 patients, showing significantly decreased viral load with Sinomarin Plus Algae nasal irrigation. Sinomarin Plus Algae is a hypertonic seawater solution with algal and herbal natural ingredients with a pH of 7.5-8 [163].

The treatment group received nasal irrigation every 4 hours, 16 hours per day, for 2 days. Nasopharyngeal swabs were taken at baseline and 48 hours later to measure viral load. The treatment group showed a significant increase in cycle threshold values, indicating decreased viral load, while no difference was seen in the control group. The treatment was well tolerated with only mild adverse effects.

Alkalinization is one possible mechanism of action - SARS-CoV-2 requires acidic pH for infection [1] and the solution has pH 7.5-8. Other possible mechanisms include antiviral activity of ingredients (e.g., fucoidan from Undaria pinnatifida) and physical removal of viral particles.

Salva



Retrospective 383 hospitalized COVID-19 patients in Argentina showing significantly lower mortality and shorter hospital stay with nebulized sodium ibuprofenate compared to 195 contemporaneous controls.

The treatment appears to be the same as detailed in [161], which reports a pH of 8.5. *Kreutzberger et al.* showed that SARS-CoV-2 requires an acidic pH (between 6.2-6.8) for membrane fusion and cell entry, even when the viral spike protein is primed by proteases like TMPRSS2. Efficacy seen here may be more due to alkalinization, which shows more consistent higher efficacy than ibuprofen in studies to date.

Baseline SpO2 was significantly different for the patients on mechanical ventilation at baseline.

Soares



Analysis of 76 ICU patients in Brazil, 44 treated with bronchoalveolar lavage using 3% sodium bicarbonate, showing significantly lower mortality with treatment.

Bronchoalveolar lavage with 10ml of sodium bicarbonate solution directly into the tube (closed circuit), 500µl for each lung segment, followed by aspiration of the solution, performed every 6 hours for 7 days.

Wang



RCT 55 mild/moderate patients in China, showing shorter hospitalization with sodium bicarbonate nasal irrigation and oral rinsing. Oral rinse with 5% sodium bicarbonate solution three times daily. Nasal irrigation two times with the solution entering through one nostril and exiting from the other. 30-40mL of solution was used every time and irrigation was performed for at least 30s. Details of randomization are not provided.

Yilmaz



RCT 60 outpatients with mild COVID-19 showing improved viral clearance with hypertonic alkaline (pH 9.3) nasal irrigation. All patients received HCQ. The nasal irrigation group had no hospitalizations, while 3 patients in the control group required hospitalization, associated with viral load increase at day 3.

Appendix 1. Methods and Data

Search methods

We perform ongoing searches of PubMed, medRxiv, Europe PMC, ClinicalTrials.gov, The Cochrane Library, Google Scholar, Research Square, ScienceDirect, Oxford University Press, the reference lists of other studies and meta-analyses, and submissions to the site c19early.org, which regularly receives notification of studies upon publication. Search terms are alkalinization and COVID-19 or SARS-CoV-2. Automated searches are performed twice daily, with all matches reviewed for inclusion. All studies regarding the use of alkalinization for COVID-19 that report a comparison with a control group are included in the main analysis. Studies with major unexplained data issues, for example major outcome data that is impossible to be correct with no response from the authors, are excluded.

Effect extraction

We extracted effect sizes and associated data from all studies. If studies report multiple kinds of effects then the most serious outcome is used in pooled analysis, while other outcomes are included in the outcome-specific analyses. For example, if effects for mortality and cases are reported then they are both used in specific outcome analyses, while mortality is used for pooled analysis. If symptomatic results are reported at multiple times, we use the latest time, for example if mortality results are provided at 14 days and 28 days, the results at 28 days have preference. Mortality alone is preferred over combined outcomes. Outcomes with zero events in both arms are not used, the next most serious outcome with one or more events is used. For example, in low-risk populations with no mortality, a reduction in mortality with treatment is not possible, however a reduction in hospitalization, for example, is still valuable. Clinical outcomes are considered more important than viral outcomes. When basically all patients recover in both treatment and control groups, preference for viral clearance and recovery is given to results mid-recovery where available. After most or all patients have recovered there is little or no room for an effective treatment to do better, however faster recovery is valuable. An IPD meta-analysis confirms that intermediate viral load reduction is more closely associated with hospitalization/death than later viral load reduction [164]. If only individual symptom data is available, the most serious symptom has priority, for example difficulty breathing or low SpO_2 is more important than cough.



Fig. 33. Mid-recovery results can more accurately reflect efficacy when almost all patients recover. *Mateja et al.* confirm that intermediate viral load results more accurately reflect hospitalization/death.

Statistical methods

Forest plots are computed using PythonMeta [165] with the DerSimonian and Laird random-effects model (the fixed effect assumption is not plausible in this case) and inverse variance weighting. Results are presented with 95% confidence intervals. Heterogeneity among studies was assessed using the I^2 statistic. When results provide an odds ratio, we compute the relative risk when possible, or convert to a relative risk according to *Zhang et al.* Reported confidence intervals and *p*-values are used when available, and adjusted values are used when provided. If multiple types of adjustments are reported propensity score matching and multivariable regression has preference over propensity score matching or weighting, which has preference over multivariable regression. Adjusted results have preference over unadjusted results for a more serious outcome when the adjustments significantly alter results. When needed, conversion between reported *p*-values and confidence intervals followed *Altman, Altman (B)*, and Fisher's exact test was used to calculate *p*-values for event data. If continuity correction for zero values is required, we use the reciprocal of the opposite arm with the sum of the correction factors equal to 1 [169]. Results are expressed with RR < 1.0 favoring treatment, and using the risk of a negative outcome when applicable (for example, the risk of death rather than the risk of survival). If studies only report relative continuous values such as relative times, the ratio of the time for the treatment group versus the time for the control group is used. Calculations are done in Python (3.14.7) with scipy (1.18.1), pythonmeta (1.26), numpy (2.5.2), statsmodels (0.15.0), and plotly (6.9.0). Mixed-effects meta-regression results are computed with R (4.4.0) using the metafor (4.6-0) and rms (6.8-0) packages, and using the most serious sufficiently powered outcome. For all statistical tests, a *p*-value less than 0.05 was considered statistically significant. Grobid 0.8.2 is used to parse PDF documents.

When evaluating potential effect modification across groups, we use an interaction test as described by *Altman (C) et al.* We compared the log-transformed relative risks using a *z*-test, deriving the standard error of the difference from the 95% confidence intervals. A two-sided interaction *p*-value of < 0.05 was considered a statistically significant difference in treatment effect between the groups.

Quality evaluation

Cochrane RoB 2/ROBINS-I are often used to evaluate studies, and have the advantage of providing standardized rules that can be applied with minimal understanding of the domain and study. However, the rules do not account for many real-world issues, often overemphasize or underemphasize others, and studies show low inter-rater reliability [177]. Certain domains are more applicable for these tools, however the time-sensitive nature of a pandemic, with significant mortality for every day of delay in evidence assessment, and the characteristics of COVID-19 make them inappropriate for this domain. This can be demonstrated with examples where expert RoB 2/ROBINS-I ratings do not match reality for COVID-19. *Popp et al.* use RoB 2 to classify *Reis et al.* as low risk of bias, however this is the opposite of reality—the trial not only has very high risk of bias, but has very high actual known bias, refusing to release data despite pledging to, reporting multiple impossible numbers, having blinding and randomization failure, and many other issues [179]. *Axfors et al.* use RoB 2 to classify *Horby et al.* as low risk of bias, however this is the opposite of reality—the very late treatment and excessive dosage used produces results with no relevance to recommended usage. HCQ shows poor results with late treatment and excessive dosage, and the combination shows harm [C]. *Hempenius et al.* use ROBINS-I to classify 33 studies for HCQ. The two rated as having the lowest risk of bias [175,176] are far from the most informative. Both involve very late treatment, providing no information on recommended usage, and ROBINS-I does a very poor job of accounting for the impact of confounding factors [D].

Our quality evaluation focuses on known issues and bias, and the potential impact on outcomes, rather than just the risk of bias. The estimated potential impact of each confounding factor, and the direction of the impact is considered. For example, consider a study that shows significantly lower risk, the value of the study varies significantly if confounding points to an underestimate or an overestimate of efficacy. In one case, the real effect may be null, while the other case provides stronger evidence of efficacy (which may be greater than the study shows). Analysis focusing on the risk of bias, while simpler, may penalize studies for theoretical or technical issues that have no or minimal impact on outcomes. Analysis also depends on the outcome, for example certain issues are less relevant for objective outcomes such as mortality. Inaccurate penalization, and inaccurate high-quality evaluation in the face of known major issues affecting outcomes, increases in significance during a pandemic when immediate recognition of new evidence is critical, and when considering all global studies, as required during a pandemic. Investigators in other countries may have different customs for design, analysis, and reporting, and different English language skills, however they may not be less diligent or have greater bias. Investigators in lower-pharmaceutical-profit countries may have lower bias towards profitable interventions.

Treatment time

We have classified studies as early treatment if most patients are not already at a severe stage at the time of treatment (for example based on oxygen status or lung involvement), and treatment started within 5 days of the onset of symptoms. If studies contain a mix of early treatment and late treatment patients, we consider the treatment time of patients contributing most to the events (for example, consider a study where most patients are treated early but late treatment patients are included, and all mortality events were observed with late treatment patients). We note that a shorter time may be preferable. Antivirals are typically only considered effective when used within a shorter timeframe, for example 0-36 or 0-48 hours for oseltamivir, with longer delays not being effective [67,68].

Living analysis

This is a living analysis and is updated regularly. We received no funding, this research is done in our spare time. We have no affiliation with any pharmaceu-

tical companies, supplement companies, governments, political parties, or advocacy organizations.

A summary of study results is below. Please submit updates and corrections at https://c19early.org/phmeta.html.

Early treatment

Effect extraction follows pre-specified rules as detailed above and gives priority to more serious outcomes. For pooled analyses, the first (most serious) outcome is used, which may differ from the effect a paper focuses on. Other outcomes are used in outcome specific analyses.

de Gabory, 2/20/2024, Randomized Controlled Trial, France, peer-reviewed, 4 authors, study period July 2021 - March 2022, trial NCT04916639 (history) (SeaCare).	risk of progression, 74.9% lower, RR 0.25, $p < 0.001$, treatment 7 of 82 (8.5%), control 31 of 91 (34.1%), NNT 3.9, day 21.
	risk of progression, 67.6% lower, RR 0.32, $p = 0.003$, treatment 7 of 82 (8.5%), control 24 of 91 (26.4%), NNT 5.6, day 14.
	risk of progression, 35.3% lower, RR 0.65, $p = 0.47$, treatment 7 of 82 (8.5%), control 12 of 91 (13.2%), NNT 22, day 7.
	recovery time, 24.2% lower, relative time 0.76, $p = 0.02$, treatment mean 5.0 (±4.1) n=82, control mean 6.6 (±4.8) n=91, time to resume daily activities.
	recovery time, 17.0% lower, relative time 0.83, $p < 0.001$, treatment 82, control 91, all symptoms combined.
	recovery time, 25.5% lower, relative time 0.74, $p = 0.03$, treatment mean 3.5 (±2.8) n=82, control mean 4.7 (±4.2) n=91, dyspnea.
	recovery time, 29.5% lower, relative time 0.71, $p < 0.001$, treatment mean 6.7 (±5.2) n=82, control mean 9.5 (±5.7) n=91, loss of smell.
	recovery time, 25.6% lower, relative time 0.74, $p = 0.005$, treatment mean 6.7 (±5.6) n=82, control mean 9.0 (±5.1) n=91, loss of taste.
	recovery time, 13.8% lower, relative time 0.86, $p = 0.22$, treatment mean 5.6 (±5.0) n=82, control mean 6.5 (±4.6) n=91, post-nasal drip.
	recovery time, 10.7% lower, relative time 0.89, $p = 0.36$, treatment mean 5.0 (±4.7) n=82, control mean 5.6 (±3.9) n=91, facial pain.
	recovery time, 1.8% higher, relative time 1.02, $p = 0.89$, treatment mean 5.6 (±5.0) n=82, control mean 5.5 (±4.6) n=91, sore throat.
	recovery time, 25.5% lower, relative time 0.75, $p = 0.04$, treatment mean 3.8 (±3.5) n=82, control mean 5.1 (±4.6) n=91, chest congestion.
	recovery time, 3.3% lower, relative time 0.97, $p = 0.78$, treatment mean 5.8 (±5.0) n=82, control mean 6.0 (±4.5) n=91, headache.
	recovery time, 14.0% lower, relative time 0.86, $p = 0.20$, treatment mean 4.9 (±3.8) n=82, control mean 5.7 (±4.4) n=91, loss of appetite.
	risk of no viral clearance, 36.6% lower, RR 0.63, $p = 0.54$, treatment 4 of 82 (4.9%), control 7 of 91 (7.7%), NNT 36, day 21.
Yilmaz, 11/19/2021, Single Blind Randomized Controlled Trial, Turkey, peer-reviewed, 8 authors, study period July 2020 - September 2020.	risk of hospitalization, 85.7% lower, RR 0.14, $p = 0.24$, treatment 0 of 30 (0.0%), control 3 of 30 (10.0%), NNT 10.0, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
	relative viral load density, 62.0% better, RR 0.38, $p = 0.87$, treatment median 15.0 IQR 43.0 n=30, control median 39.51 IQR 1085.1 n=30, day 7.
	relative viral load density, 42.9% better, RR 0.57, $p = 0.95$, treatment median 1747 IQR 5863.5 n=30, control median 3058 IQR 145568.9 n=30, day 3.

Late treatment

Effect extraction follows pre-specified rules as detailed above and gives priority to more serious outcomes. For pooled analyses, the first (most serious) outcome is used, which may differ from the effect a paper focuses on. Other outcomes are used in outcome specific analyses.

Calonico, 5/31/2022, retrospective, Argentina, peer-reviewed, 3 authors, study period March 2020 - September 2021, this trial uses multiple treatments in the treatment arm (combined with sodium ibuprofenate) - results of individual treatments may vary.	risk of death, 48.7% lower, RR 0.51, $p = 0.01$, treatment 1,019, control 3,303.
Delić, 5/28/2022, Randomized Controlled Trial, Croatia, peer-reviewed, 12 authors, study period October 2020 - June 2021, trial NCT04755972 (history).	risk of death, 23.0% lower, RR 0.77, $p = 0.13$, treatment 23 of 42 (54.8%), control 37 of 52 (71.2%), NNT 6.1, ICU mortality.
	risk of death, 20.1% lower, RR 0.80, $p = 0.30$, treatment 20 of 42 (47.6%), control 31 of 52 (59.6%), NNT 8.3, 28 day mortality.
El-Badrawy, 11/18/2022, Double Blind Randomized Controlled Trial, placebo-controlled, Egypt, peer-reviewed, 8 authors, study period 2 September, 2021 - 30 April, 2022, trial NCT05035524 (history) (SODIC).	risk of death, 23.2% lower, RR 0.77, $p = 0.26$, treatment 32 of 272 (11.8%), control 42 of 274 (15.3%), NNT 28, all cases.
	risk of death, 54.8% lower, RR 0.45, $p = 0.02$, treatment 12 of 247 (4.9%), control 27 of 251 (10.8%), NNT 17, mild/moderate/severe cases.
	risk of death, 79.2% lower, RR 0.21, $p = 0.21$, treatment 1 of 125 (0.8%), control 5 of 130 (3.8%), NNT 33, moderate cases.
	risk of death, 53.2% lower, RR 0.47, $p = 0.02$, treatment 11 of 63 (17.5%), control 22 of 59 (37.3%), NNT 5.0, severe cases.
	risk of death, 22.7% higher, RR 1.23, $p = 0.33$, treatment 20 of 25 (80.0%), control 15 of 23 (65.2%), critical cases.
	recovery time, 27.6% lower, relative time 0.72, $p < 0.001$, treatment mean 4.2 (±2.5) n=272,

	control mean 5.8 (±3.1) n=274, time to clinical improvement.
	CT score, 33.3% lower, RR 0.67, p = 0.001, treatment 238, control 229, CT score, day 30.
El-Badrawy (B), 6/12/2022, prospective, Egypt, peer-reviewed, 7 authors, study period 15 April, 2020 - 31 August, 2020, trial NCT04374591 (history).	risk of death, 56.7% lower, RR 0.43, p = 0.37, treatment 3 of 127 (2.4%), control 3 of 55 (5.5%), NNT 32.
	risk of progression, 39.4% lower, RR 0.61, p = 0.52, treatment 7 of 127 (5.5%), control 5 of 55 (9.1%), NNT 28, deterioration or death, day 30.
	risk of no recovery, 19.2% lower, RR 0.81, p = 0.03, treatment 84 of 127 (66.1%), control 45 of 55 (81.8%), NNT 6.4, day 30.
	relative CT score, 72.7% better, RR 0.27, p < 0.001, treatment 127, control 55, day 30.
	recovery time, 66.2% lower, relative time 0.34, p < 0.001, treatment mean 3.31 (±0.99) n=127, control mean 9.79 (±6.29) n=55, time to clinical improvement.
Kalayan, 12/31/2022, retrospective, Argentina, peer-reviewed, 10 authors, study period June 2020 - September 2020, this trial uses multiple treatments in the treatment arm (combined with sodium ibuprofenate) - results of individual treatments may vary.	risk of death, 79.1% lower, RR 0.21, p < 0.001, treatment 3 of 37 (8.1%), control 24 of 62 (38.7%), NNT 3.3.
Lumlertgul, 3/7/2025, Randomized Controlled Trial, United Kingdom, peer-reviewed, median age 48.0, 6 authors, study period July 2021 - January 2022, trial NCT04655716 (history).	risk of death, 66.7% lower, RR 0.33, p = 0.57, treatment 1 of 8 (12.5%), control 3 of 8 (37.5%), NNT 4.0, day 60.
	AKI, 40.0% lower, RR 0.60, p = 0.62, treatment 3 of 8 (37.5%), control 5 of 8 (62.5%), NNT 4.0.
Mody, 3/19/2021, Randomized Controlled Trial, India, peer-reviewed, 1 author, study period July 2020 - September 2020, trial CTRI/2020/07/026535.	risk of no improvement, 63.6% lower, RR 0.36, p < 0.001, treatment 8 of 30 (26.7%), control 22 of 30 (73.3%), NNT 2.1.
Pantazopoulos, 7/3/2023, Single Blind Randomized Controlled Trial, Greece, peer-reviewed, mean age 63.6, 7 authors, study period June 2022 - December 2022, average treatment delay 9.5 days, trial NCT05729204 (history).	risk of death, 66.7% lower, RR 0.33, p = 1.00, treatment 0 of 28 (0.0%), control 1 of 28 (3.6%), NNT 28, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
	risk of ICU admission, 66.7% lower, RR 0.33, p = 1.00, treatment 0 of 28 (0.0%), control 1 of 28 (3.6%), NNT 28, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
	risk of oxygen therapy, 80.0% lower, RR 0.20, p = 0.49, treatment 0 of 28 (0.0%), control 2 of 28 (7.1%), NNT 14, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), high flow nasal cannula or non-invasive ventilation.
	risk of no viral clearance, 42.1% lower, RR 0.58, p = 0.04, treatment 11 of 28 (39.3%), control 19 of 28 (67.9%), NNT 3.5.
Salva, 8/30/2021, retrospective, Argentina, peer-reviewed, 26 authors, study period 4 April, 2020 - 31 October, 2020, this trial uses multiple treatments in the treatment arm (combined with sodium ibuprofenate) - results of individual treatments may vary, trial NCT04382768 (history).	risk of death, 45.2% lower, RR 0.55, p = 0.009, treatment 35 of 327 (10.7%), control 34 of 174 (19.5%), NNT 11, patients not on mechanical ventilation at baseline.
	risk of death, 75.7% lower, RR 0.24, p < 0.001, treatment 11 of 56 (19.6%), control 17 of 21 (81.0%), NNT 1.6, patients on mechanical ventilation at baseline.
	hospitalization time, 13.5% lower, relative time 0.86, p < 0.001, treatment mean 11.5 (±0.3) n=327, control mean 13.3 (±0.9) n=174, patients not on mechanical ventilation at baseline.
	hospitalization time, 17.8% lower, relative time 0.82, p < 0.001, treatment mean 14.8 (±1.4) n=56, control mean 18.0 (±5.6) n=21, patients on mechanical ventilation at baseline.
Soares, 12/29/2021, prospective, Brazil, peer-reviewed, 17 authors, study period December 2020 - May 2021.	risk of death, 75.8% lower, RR 0.24, p < 0.001, treatment 6 of 44 (13.6%), control 18 of 32 (56.2%), NNT 2.3.
Wang (B), 3/15/2023, Randomized Controlled Trial, China, peer-reviewed, 13 authors.	hospitalization time, 38.5% lower, relative time 0.61, p < 0.001, treatment mean 7.7 (±4.15) n=23, control mean 12.53 (±5.56) n=32.

Prophylaxis

Effect extraction follows pre-specified rules as detailed above and gives priority to more serious outcomes. For pooled analyses, the first (most serious) outcome is used, which may differ from the effect a paper focuses on. Other outcomes are used in outcome specific analyses.

Karami, 1/9/2024, Double Blind Randomized Controlled Trial, Iran, peer-reviewed, 4 authors, study period July 2022 - October 2022, trial IRCT20220328054364N1.	relative mean total symptoms, 45.5% better, RR 0.55, p = 0.14, treatment mean 2.52 (±4.99) n=40, control mean 4.62 (±7.37) n=40.
	relative mean week 1 symptoms, 42.6% better, RR 0.57, p = 0.39, treatment mean 0.7 (±1.84) n=36, control mean 1.22 (±3.14) n=40.
	relative mean week 2 symptoms, 42.0% better, RR 0.58, p = 0.27, treatment mean 0.87 (±2.26) n=36, control mean 1.5 (±2.63) n=40.
	relative mean week 3 symptoms, 79.4% better, RR 0.21, p = 0.045, treatment mean 0.2 (±0.72) n=36, control mean 0.97 (±2.16) n=40.
	relative mean week 4 symptoms, 18.5% better, RR 0.82, p = 0.77, treatment mean 0.75 (±2.43) n=36, control mean 0.92 (±2.58) n=40.
	risk of case, 38.9% lower, RR 0.61, p = 0.16, treatment 11 of 40 (27.5%), control 18 of 40 (45.0%), NNT 5.7.

Evaluation Notes

Analyzing the data from first principles is always important, and may be especially important for COVID-19. Bias in the design, analysis, and reporting of clinical studies has long been reported, and may be increased for COVID-19 due to politicization. For example, Scott Alexander noted that *"if you say anything in favor of ivermectin you will be cast out of civilization and thrown into the circle of social hell reserved for Klan members and 1/6 insurrectionists. All the health officials in the world will shout 'horse dewormer!' at you and compare you to Josef Mengele."* [64] Social pressure to report politically acceptable results was very strong. There may therefore be unusually strong bias in design, analysis, and reporting. For example, Prof. Greenland reports that *Hayward et al.* applied an unjustified and undisclosed extremely tight, null-centered Bayesian prior that biases towards more politically acceptable results [197]. While the politicization focused on certain treatments, it was not limited to them. For example, media coverage was highly biased against positive results for low-cost treatments [198] across the 226 treatments we cover. Studies should be evaluated from first principles, incorporating the treatment delay, treatment regimen, patient population, and other confounding factors. For COVID-19, there is no significant difference in the results of RCTs compared to observational studies, RR 0.97 [0.91-1.03] [58]—in both cases bias varies from minimal to extreme, and all studies must be evaluated individually.

US authorities claim only three high-profit drugs from companies with strong US lobbying are beneficial for early treatment (2 repurposed drugs - remdesivir and molnupiravir, and one novel drug - nirmatrelvir) [E]. COVID-19 involves the interplay of many viral and host proteins and factors, providing over 500 therapeutic targets [108]. Given the 12,000+ proposed treatments [46], existing results for many treatments with overlapping secondary complications and therapeutic targets, and the combination of known safety and pharmocokinetics for certain treatments along with strong mechanistic evidence, the probability of only 3 high-profit drugs from top lobbying companies being beneficial is extremely low. This likely reflects a bias toward evaluation of drugs with strong financial resources and efforts devoted to passing the US approval process, and very limited or non-existing evaluation of low-cost treatments. Indeed, official recommendations varied widely between countries [199]. Some countries evaluated limited low-cost treatments early and 25 low-cost treatments were approved in one or more countries [199].

Contrary to claims found online, we analyze both all studies and higher-quality studies (with evaluation focusing on known issues and bias, and the potential impact on outcomes, rather than just the risk of bias), we analyze specific outcomes and pooled outcomes (with extensive analysis and validation of pooled outcomes), and we do not include preclinical studies or retracted studies in meta-analysis. Pooled outcomes can detect efficacy earlier but do not bias towards efficacy—the inclusion of less appropriate designs such as very late treatment may hide efficacy for appopriate use.

Supplementary Data

Supplementary Data

Footnotes

a. Viral infection and replication involves attachment, entry, uncoating and release, genome replication and transcription, translation and protein processing, assembly and budding, and release. Each step can be disrupted by therapeutics.

b. Smoking was known to cause lung cancer since at least 1939, but this was not widely recognized in the US until 1964, 25 years later. Surgeon general Leroy Burney tried publicizing the danger starting in 1957, with limited success. Surgeon general Luther Terry, appointed in 1961, prompted by President Kennedy in 1962 amid pressure from health advocates, finally got recognition in 1964. The 1964 report reviewed 7,000+ studies, but these could (and should) have been reviewed and acted upon in real-time as they were published. Historians attribute the 25 year delay to an industry campaign to manufacture doubt and controversy, through tactics like funding biased and fraudulent research from "independent" organizations, attacking scientists, and political lobbying. The success of the industry campaign is only possible because officials did not analyze the research in detail. Fraudulent industry research supported prior failures, but would have been called out as fraudulent by officials that analyzed and understood the research in real-time.

c. When administered late in infection, HCQ may enhance viral egress by further increasing lysosomal pH beyond the effect of ORF3a's water channel activity, thereby promoting lysosomal exocytosis, inactivating degradative enzymes, and facilitating the release of SARS-CoV-2 particles into the extracellular environment [171,172]. Research also suggests potential cardioprotective effects at lower doses, but cardiotoxicity with excessive dosage [173]. *Bobrowski et al.* also indicate negative effects if HCQ and remdesivir are combined.

d. *Peters (B) et al.* is subject to confounding by calendar-time (SOC evolved rapidly early in the pandemic, the linear covariate does not reflect non-linear SOC changes and hospital specific effects), hospital type (non-treatment hospitals were tertiary university centers), confounding by indication (4/7 hospitals initiated treatment on deterioration), immortal-time bias for as-treated (exposure assigned after baseline), significant differences for other experimental treatments, potential overadjustment from collider bias (steroid use and indication bias), limited baseline severity information, differences in hospice referral propensity across hospitals, unadjusted difference in time from onset to admission, difference in PCR positivity, and other factors. *Mahévas et al.* is subject to confounding by hospital (treatment highly dependent on the hospital, different SOC/ICU transfer practices, not included in PS), immortal time (only partly addressed in sensitivity analysis), co-treatment differences, calendar-time (SOC evolved rapidly early in the pandemic), binary coding for age (age ≥65 despite steep age-risk gradient), residual imbalance (variables dropped from PS), a composite outcome dependent on hospital triage/capacity, and other factors.

e. Monoclonal antibodies were previously included. Other treatments such as dexamethasone, tocilizumab, and baricitinib were recommended for late stage hospitalized patients.

References

1. ***Kreutzberger*** et al., *SARS-CoV-2 requires acidic pH to infect cells*, Proceedings of the National Academy of Sciences, doi:10.1073/pnas.2209514119.
2. ***Covid Analysis***, *Sodium Bicarbonate reduces COVID-19 risk: real-time meta-analysis of 6 studies (Version 2)*, c19early.org/sbmeta.html.
3. ***Shafiee*** et al., *Alkalinization Using Sodium Bicarbonate for COVID-19 Treatment: A Systematic Review and Meta-Analysis*, Journal of Evidence-Based Integrative Medicine, doi:10.1177/2515690x241258403.
4. ***Ryu*** et al., *Fibrin drives thromboinflammation and neuropathology in COVID-19*, Nature, doi:10.1038/s41586-024-07873-4.
5. ***Dai*** et al., *Neurological complications of COVID-19*, QJM: An International Journal of Medicine, doi:10.1093/qjmed/hcac272.
6. ***Rong*** et al., *Persistence of spike protein at the skull-meninges-brain axis may contribute to the neurological sequelae of COVID-19*, Cell Host & Microbe, doi:10.1016/j.chom.2024.11.007.
7. ***Yang*** et al., *SARS-CoV-2 infection causes dopaminergic neuron senescence*, Cell Stem Cell, doi:10.1016/j.stem.2023.12.012.

8. **Scardua-Silva** et al., *Microstructural brain abnormalities, fatigue, and cognitive dysfunction after mild COVID-19*, Scientific Reports, doi:10.1038/s41598-024-52005-7.
9. **Hampshire** et al., *Cognition and Memory after Covid-19 in a Large Community Sample*, New England Journal of Medicine, doi:10.1056/NEJMoa2311330.
10. **Duloquin** et al., *Is COVID-19 Infection a Multiorganic Disease? Focus on Extrapulmonary Involvement of SARS-CoV-2*, Journal of Clinical Medicine, doi:10.3390/jcm13051397.
11. **Sodagar** et al., *Pathological Features and Neuroinflammatory Mechanisms of SARS-CoV-2 in the Brain and Potential Therapeutic Approaches*, Biomolecules, doi:10.3390/biom12070971.
12. **Sagar** et al., *COVID-19-associated cerebral microbleeds in the general population*, Brain Communications, doi:10.1093/braincomms/fcae127.
13. **Verma** et al., *Persistent Neurological Deficits in Mouse PASC Reveal Antiviral Drug Limitations*, bioRxiv, doi:10.1101/2024.06.02.596989.
14. **Panagea** et al., *Neurocognitive Impairment in Long COVID: A Systematic Review*, Archives of Clinical Neuropsychology, doi:10.1093/arclin/acae042.
15. **Ariza** et al., *COVID-19: Unveiling the Neuropsychiatric Maze—From Acute to Long-Term Manifestations*, Biomedicines, doi:10.3390/biomedicines12061147.
16. **Vashisht** et al., *Neurological Complications of COVID-19: Unraveling the Pathophysiological Underpinnings and Therapeutic Implications*, Viruses, doi:10.3390/v16081183.
17. **Ahmad** et al., *Neurological Complications and Outcomes in Critically Ill Patients With COVID-19: Results From International Neurological Study Group From the COVID-19 Critical Care Consortium*, The Neurohospitalist, doi:10.1177/19418744241292487.
18. **Wang** et al., *SARS-CoV-2 membrane protein induces neurodegeneration via affecting Golgi-mitochondria interaction*, Translational Neurodegeneration, doi:10.1186/s40035-024-00458-1.
19. **Freitas** et al., *Central nervous system and systemic inflammatory networks associated with acute neurological outcomes in COVID-19*, Scientific Reports, doi:10.1038/s41598-025-08632-9.
20. **Lu** et al., *Risk of neuropsychiatric and related conditions associated with SARS-CoV-2 infection: a difference-in-differences analysis*, Nature Communications, doi:10.1038/s41467-025-61961-1.
21. **Jachman-Kapułka** et al., *Cross-Section of Neurological Manifestations Among SARS-CoV-2 Omicron Subvariants—Single-Center Study*, Brain Sciences, doi:10.3390/brainsci14111161.
22. **Beckman** et al., *SARS-CoV-2 infects neurons and induces neuroinflammation in a non-human primate model of COVID-19*, Cell Reports, doi:10.1016/j.celrep.2022.111573.
23. **Eberhardt** et al., *SARS-CoV-2 infection triggers pro-atherogenic inflammatory responses in human coronary vessels*, Nature Cardiovascular Research, doi:10.1038/s44161-023-00336-5.
24. **Van Tin** et al., *Spike Protein of SARS-CoV-2 Activates Cardiac Fibrogenesis through NLRP3 Inflammasomes and NF-κB Signaling*, Cells, doi:10.3390/cells13161331.
25. **Borka Balas** et al., *COVID-19 and Cardiac Implications—Still a Mystery in Clinical Practice*, Reviews in Cardiovascular Medicine, doi:10.31083/j.rcm2405125.
26. **AlTaweel** et al., *An In-Depth Insight into Clinical, Cellular and Molecular Factors in COVID19-Associated Cardiovascular Ailments for Identifying Novel Disease Biomarkers, Drug Targets and Clinical Management Strategies*, Archives of Microbiology & Immunology, doi:10.26502/ami.936500177.
27. **Saha** et al., *COVID-19 beyond the lungs: Unraveling its vascular impact and cardiovascular complications—mechanisms and therapeutic implications*, Science Progress, doi:10.1177/00368504251322069.
28. **Yin** et al., *COVID-19: a vascular nightmare unfolding*, Frontiers in Immunology, doi:10.3389/fimmu.2025.1593885.
29. **Bruno** et al., *Accelerated vascular ageing after COVID-19 infection: the CARTESIAN study*, European Heart Journal, doi:10.1093/eurheartj/ehaf430.
30. **Abiri** et al., *The silent legacy of COVID-19: exploring genomic instability in long-term COVID-19 survivors*, BMC Infectious Diseases, doi:10.1186/s12879-025-11419-y.
31. **Gioia** et al., *SARS-CoV-2 infection induces DNA damage, through CHK1 degradation and impaired 53BP1 recruitment, and cellular senescence*, Nature Cell Biology, doi:10.1038/s41556-023-01096-x.
32. **Doğan** et al., *Clinical Investigation of Leukocyte DNA Damage in COVID-19 Patients*, Current Issues in Molecular Biology, doi:10.3390/cimb45020062.
33. **Rueda-Torres** et al., *Longitudinal Assessment of DNA Damage in PBMCs From Hospitalized COVID-19 Patients via Alkaline Comet Assay*, Environmental and Molecular Mutagenesis, doi:10.1002/em.70055.
34. **Trender** et al., *Changes in memory and cognition during the SARS-CoV-2 human challenge study*, eClinicalMedicine, doi:10.1016/j.eclinm.2024.102842.
35. **Wu** et al., *SARS-CoV-2 replication in airway epithelia requires motile cilia and microvillar reprogramming*, Cell, doi:10.1016/j.cell.2022.11.030.
36. **Demarco**, S., *Shadowing SARS-CoV-2 Through Mucus and Cilia*, DDN, viewonline.drugdiscoverynews.com/hubfs/DDN%20Milestones/Shadowing%20SARS-CoV-2%20Through%20Mucus%20a...
37. **Lee** et al., *ACE2 localizes to the respiratory cilia and is not increased by ACE inhibitors or ARBs*, Nature Communications, doi:10.1038/s41467-020-19145-6.
38. **Dugied** et al., *Multimodal SARS-CoV-2 interactome sketches the virus-host spatial organization*, Communications Biology, doi:10.1038/s42003-025-07933-z.
39. **Malone** et al., *Structures and functions of coronavirus replication–transcription complexes and their relevance for SARS-CoV-2 drug design*, Nature Reviews Molecular Cell Biology, doi:10.1038/s41580-021-00432-z.
40. **Murigneux** et al., *Proteomic analysis of SARS-CoV-2 particles unveils a key role of G3BP proteins in viral assembly*, Nature Communications, doi:10.1038/s41467-024-44958-0.
41. **Lv** et al., *Host proviral and antiviral factors for SARS-CoV-2*, Virus Genes, doi:10.1007/s11262-021-01869-2.
42. **Lui** et al., *Nsp1 facilitates SARS-CoV-2 replication through calcineurin-NFAT signaling*, Virology, doi:10.1128/mbio.00392-24.
43. **Niarakis** et al., *Drug-target identification in COVID-19 disease mechanisms using computational systems biology approaches*, Frontiers in Immunology, doi:10.3389/fimmu.2023.1282859.
44. **Katiyar** et al., *SARS-CoV-2 Assembly: Gaining Infectivity and Beyond*, Viruses, doi:10.3390/v16111648.
45. **Wu (B)** et al., *Decoding the genome of SARS-CoV-2: a pathway to drug development through translation inhibition*, RNA Biology, doi:10.1080/15476286.2024.2433830.
46. **c19early.org**, c19early.org/treatments.html.
47. **Effros** et al., *The in vivo pH of the extravascular space of the lung*, Journal of Clinical Investigation, doi:10.1172/JCI106164.
48. **Liu** et al., *Nanoantidote for repression of acidosis pH promoting COVID-19 infection*, VIEW, doi:10.1002/VIW.20220004.
49. **Jimenez** et al., *Acid pH Increases SARS-CoV-2 Infection and the Risk of Death by COVID-19*, Frontiers in Medicine, doi:10.3389/fmed.2021.637885.
50. **Jadad** et al., *Randomized Controlled Trials: Questions, Answers, and Musings, Second Edition*, doi:10.1002/9780470691922.
51. **Gøtzsche**, P., *Bias in double-blind trials*, Doctoral Thesis, University of Copenhagen, www.scientificfreedom.dk/2023/05/16/bias-in-double-blind-trials-doctoral-thesis/.
52. **Als-Nielsen** et al., *Association of Funding and Conclusions in Randomized Drug Trials*, JAMA, doi:10.1001/jama.290.7.921.

53. **Bekelman** et al., *Scope and Impact of Financial Conflicts of Interest in Biomedical Research*, JAMA, doi:10.1001/jama.289.4.454.

54. **Lundh** et al., *Industry sponsorship and research outcome*, Cochrane Database of Systematic Reviews, doi:10.1002/14651858.MR000033.pub3.

55. ***c19early.org (B)***, c19early.org/phsupp.html#fig_rctobs.

56. **Concato** et al., *Randomized, Controlled Trials, Observational Studies, and the Hierarchy of Research Designs*, New England Journal of Medicine, doi:10.1056/NEJM200006223422507.

57. **Anglemyer** et al., *Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials*, Cochrane Database of Systematic Reviews, doi:10.1002/14651858.MR000034.pub2.

58. ***c19early.org (C)***, c19early.org/rctobs.html.

59. **Lee (B)** et al., *Analysis of Overall Level of Evidence Behind Infectious Diseases Society of America Practice Guidelines*, Arch Intern Med., 2011, 171:1, 18-22, doi:10.1001/archinternmed.2010.482.

60. **Deaton** et al., *Understanding and misunderstanding randomized controlled trials*, Social Science & Medicine, 210, doi:10.1016/j.socscimed.2017.12.005.

61. **Nichol** et al., *Challenging issues in randomised controlled trials*, Injury, 2010, doi:10.1016/j.injury.2010.03.033, www.injuryjournal.com/article/S0020-1383(10)00233-0/fulltext.

62. **Akash** et al., *On a model-based approach to improve intranasal spray targeting for respiratory viral infections*, Frontiers in Drug Delivery, doi:10.3389/fddev.2023.1164671.

63. **Hossain** et al., *Mechanics-guided parametric modeling of intranasal spray devices and formulations for targeted drug delivery to the nasopharynx*, Frontiers in Drug Delivery, doi:10.3389/fddev.2025.1721960.

64. **web.archive.org**, web.archive.org/web/20211117052139/https://astralcodexten.substack.com/p/ivermectin-much-more-than-y...

65. **altmetric.com**, www.altmetric.com/.

66. **help.altmetric.com**, help.altmetric.com/support/solutions/articles/6000235983-attention-sources-tracked-by-altmetric.

67. **Treanor** et al., *Efficacy and Safety of the Oral Neuraminidase Inhibitor Oseltamivir in Treating Acute Influenza: A Randomized Controlled Trial*, JAMA, 2000, 283:8, 1016-1024, doi:10.1001/jama.283.8.1016.

68. **McLean** et al., *Impact of Late Oseltamivir Treatment on Influenza Symptoms in the Outpatient Setting: Results of a Randomized Trial*, Open Forum Infect. Dis. September 2015, 2:3, doi:10.1093/ofid/ofv100.

69. **Ikematsu** et al., *Baloxavir Marboxil for Prophylaxis against Influenza in Household Contacts*, New England Journal of Medicine, doi:10.1056/NEJMoa1915341.

70. **Hayden** et al., *Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents*, New England Journal of Medicine, doi:10.1056/NEJMoa1716197.

71. **Kumar** et al., *Combining baloxavir marboxil with standard-of-care neuraminidase inhibitor in patients hospitalised with severe influenza (FLAGSTONE): a randomised, parallel-group, double-blind, placebo-controlled, superiority trial*, The Lancet Infectious Diseases, doi:10.1016/S1473-3099(21)00469-2.

72. **López-Medina** et al., *Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19: A Randomized Clinical Trial*, JAMA, doi:10.1001/jama.2021.3071.

73. **Korves** et al., *SARS-CoV-2 Genetic Variants and Patient Factors Associated with Hospitalization Risk*, medRxiv, doi:10.1101/2024.03.08.24303818.

74. **Faria** et al., *Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil*, Science, doi:10.1126/science.abh2644.

75. **Nonaka** et al., *SARS-CoV-2 variant of concern P.1 (Gamma) infection in young and middle-aged patients admitted to the intensive care units of a single hospital in Salvador, Northeast Brazil, February 2021*, International Journal of Infectious Diseases, doi:10.1016/j.ijid.2021.08.003.

76. **Karita** et al., *Trajectory of viral load in a prospective population-based cohort with incident SARS-CoV-2 G614 infection*, medRxiv, doi:10.1101/2021.08.27.21262754.

77. **Zavascki** et al., *Advanced ventilatory support and mortality in hospitalized patients with COVID-19 caused by Gamma (P.1) variant of concern compared to other lineages: cohort study at a reference center in Brazil*, Research Square, doi:10.21203/rs.3.rs-910467/v1.

78. **Willett** et al., *The hyper-transmissible SARS-CoV-2 Omicron variant exhibits significant antigenic change, vaccine escape and a switch in cell entry mechanism*, medRxiv, doi:10.1101/2022.01.03.21268111.

79. **Peacock** et al., *The SARS-CoV-2 variant, Omicron, shows rapid replication in human primary nasal epithelial cultures and efficiently uses the endosomal route of entry*, bioRxiv, doi:10.1101/2021.12.31.474653.

80. **Williams**, T., *Not All Ivermectin Is Created Equal: Comparing The Quality of 11 Different Ivermectin Sources*, Do Your Own Research, doyourownresearch.substack.com/p/not-all-ivermectin-is-created-equal.

81. **Xu** et al., *A study of impurities in the repurposed COVID-19 drug hydroxychloroquine sulfate by UHPLC-Q/TOF-MS and LC-SPE-NMR*, Rapid Communications in Mass Spectrometry, doi:10.1002/rcm.9358.

82. **Jitobaom** et al., *Favipiravir and Ivermectin Showed in Vitro Synergistic Antiviral Activity against SARS-CoV-2*, Research Square, doi:10.21203/rs.3.rs-941811/v1.

83. **Jitobaom (B)** et al., *Synergistic anti-SARS-CoV-2 activity of repurposed anti-parasitic drug combinations*, BMC Pharmacology and Toxicology, doi:10.1186/s40360-022-00580-8.

84. **Jeffreys** et al., *Remdesivir-ivermectin combination displays synergistic interaction with improved in vitro activity against SARS-CoV-2*, International Journal of Antimicrobial Agents, doi:10.1016/j.ijantimicag.2022.106542.

85. **Ostrov** et al., *Highly Specific Sigma Receptor Ligands Exhibit Anti-Viral Properties in SARS-CoV-2 Infected Cells*, Pathogens, doi:10.3390/pathogens10111514.

86. **Alsaidi** et al., *Griffithsin and Carrageenan Combination Results in Antiviral Synergy against SARS-CoV-1 and 2 in a Pseudoviral Model*, Marine Drugs, doi:10.3390/md19080418.

87. **Andreani** et al., *In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect*, Microbial Pathogenesis, doi:10.1016/j.micpath.2020.104228.

88. **De Forni** et al., *Synergistic drug combinations designed to fully suppress SARS-CoV-2 in the lung of COVID-19 patients*, PLoS ONE, doi:10.1371/journal.pone.0276751.

89. **Wan** et al., *Synergistic inhibition effects of andrographolide and baicalin on coronavirus mechanisms by downregulation of ACE2 protein level*, Scientific Reports, doi:10.1038/s41598-024-54722-5.

90. **Said** et al., *The effect of Nigella sativa and vitamin D3 supplementation on the clinical outcome in COVID-19 patients: A randomized controlled clinical trial*, Frontiers in Pharmacology, doi:10.3389/fphar.2022.1011522.

91. **Fiaschi** et al., *In Vitro Combinatorial Activity of Direct Acting Antivirals and Monoclonal Antibodies against the Ancestral B.1 and BQ.1.1 SARS-CoV-2 Viral Variants*, Viruses, doi:10.3390/v16020168.

92. **Xing** et al., *Published anti-SARS-CoV-2 in vitro hits share common mechanisms of action that synergize with antivirals*, Briefings in Bioinformatics, doi:10.1093/bib/bbab249.

93. **Chen** et al., *Synergistic Inhibition of SARS-CoV-2 Replication Using Disulfiram/Ebselen and Remdesivir*, ACS Pharmacology & Translational Science, doi:10.1021/acsptsci.1c00022.

94. **Hempel** et al., *Synergistic inhibition of SARS-CoV-2 cell entry by otamixaban and covalent protease inhibitors: pre-clinical assessment of pharmacological and molecular properties*, Chemical Science, doi:10.1039/D1SC01494C.

95. **Schultz** et al., *Pyrimidine inhibitors synergize with nucleoside analogues to block SARS-CoV-2*, Nature, doi:10.1038/s41586-022-04482-x.

96. **Ohashi** et al., *Potential anti-COVID-19 agents, cepharanthine and nelfinavir, and their usage for combination treatment*, iScience, doi:10.1016/j.isci.2021.102367.

97. **Al Krad** et al., *The protease inhibitor Nirmatrelvir synergizes with inhibitors of GRP78 to suppress SARS-CoV-2 replication*, bioRxiv, doi:10.1101/2025.03.09.642200.

98. **Abd Elsalam** et al., *Anti-COVID-19 activity and simple HPLC method for concurrent detection of repurposed drugs in novel binary mixtures*, AMB Express, doi:10.1186/s13568-026-02030-8.

99. **Rana** et al., *Ivermectin and Doxycycline combination as a promising anti-viral drug candidate: an in-silico and DFT study*, In Silico Pharmacology, doi:10.1007/s40203-026-00576-w.

100. **Setz** et al., *Synergistic Virus Neutralizing Activities of European Black Elderberry Fruit Extract and Iota-Carrageenan Against SARS-CoV-2, Influenza A Virus and Respiratory Syncytial Virus*, Nutrients, doi:10.3390/nu18081205.

101. **Ali** et al., *Preclinical Screening Platform Identifies Azatadine-Dimaleate as a Potent Repurposed Therapeutic Against SARS-CoV-2 Infection*, Journal of Medical Virology, doi:10.1002/jmv.70713.

102. **Lew** et al., *Combination of Remdesivir and Ivermectin Exerts Highly Potent and Synergistic Antiviral Activity Against Murine Coronavirus and SARS-CoV-2 Infections*, Cells, doi:10.3390/cells15131146.

103. **Khatun** et al., *An All-Oral Antiviral Combination Strategy against COVID-19 Enabled by the Synergistic Mechanism of Action of Auranofin and Remdesivir*, Elsevier BV, doi:10.2139/ssrn.6942990.

104. **How** et al., *The Combination of Nirmatrelvir and Ivermectin Exerts Strongly Synergistic Antiviral and Anti-Inflammatory Effects Against Murine Coronavirus Infection of Macrophages*, International Journal of Molecular Sciences, doi:10.3390/ijms27167316.

105. **Tan** et al., *Combination Treatment With Remdesivir and Ivermectin Exerts Highly Synergistic and Potent Antiviral Activity Against Murine Coronavirus Infection*, Frontiers in Cellular and Infection Microbiology, doi:10.3389/fcimb.2021.700502.

106. **Thairu** et al., *A Comparison of Ivermectin and Non Ivermectin Based Regimen for COVID-19 in Abuja: Effects on Virus Clearance, Days-to-discharge and Mortality*, Journal of Pharmaceutical Research International, doi:10.9734/jpri/2022/v34i44A36328.

107. **Singh** et al., *The relationship between viral clearance rates and disease progression in early symptomatic COVID-19: a systematic review and meta-regression analysis*, Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkae045.

108. ***c19early.org (D)***, c19early.org/mechanisms.html.

109. **Wannigama** et al., *Early treatment with fluvoxamine, bromhexine, cyproheptadine, and niclosamide to prevent clinical deterioration in patients with symptomatic COVID-19: a randomized clinical trial*, eClinicalMedicine, 10.1016/j.eclinm.2024.102517, www.thelancet.com/journals/eclinm/article/PIIS2589-5370(24)00096-8/fulltext.

110. **Willett (B)** et al., *SARS-CoV-2 rapidly evolves lineage-specific phenotypic differences when passaged repeatedly in immune-naïve mice*, Communications Biology, doi:10.1038/s42003-024-05878-3.

111. **Zhou** et al., *Nirmatrelvir-resistant SARS-CoV-2 variants with high fitness in an infectious cell culture system*, Science Advances, doi:10.1126/sciadv.add7197.

112. **Jochmans** et al., *The Substitutions L50F, E166A, and L167F in SARS-CoV-2 3CLpro Are Selected by a Protease Inhibitor In Vitro and Confer Resistance To Nirmatrelvir*, mBio, doi:10.1128/mbio.02815-22.

113. **Lopez** et al., *SARS-CoV-2 Resistance to Small Molecule Inhibitors*, Current Clinical Microbiology Reports, doi:10.1007/s40588-024-00229-6.

114. **Zvornicanin** et al., *Molecular Mechanisms of Drug Resistance and Compensation in SARS-CoV-2 Main Protease: The Interplay Between E166 and L50*, bioRxiv, doi:10.1101/2025.01.24.634813.

115. **Vukovikj** et al., *Impact of SARS-CoV-2 variant mutations on susceptibility to monoclonal antibodies and antiviral drugs: a non-systematic review, April 2022 to October 2024*, Eurosurveillance, doi:10.2807/1560-7917.ES.2025.30.10.2400252.

116. **Iriyama** et al., *Clinical and molecular landscape of prolonged SARS-CoV-2 infection with resistance to remdesivir in immunocompromised patients*, PNAS Nexus, doi:10.1093/pnasnexus/pgaf085.

117. **Moghadasi** et al., *Rapid resistance profiling of SARS-CoV-2 protease inhibitors*, npj Antimicrobials and Resistance, doi:10.1038/s44259-023-00009-0.

118. **Nooruzzaman** et al., *Emergence of transmissible SARS-CoV-2 variants with decreased sensitivity to antivirals in immunocompromised patients with persistent infections*, Nature Communications, doi:10.1038/s41467-024-51924-3.

119. **Rudraraju** et al., *Parallel use of human stem cell lung and heart models provide insights for SARS-CoV-2 treatment*, Stem Cell Reports, doi:10.1016/j.stemcr.2023.05.007.

120. **Wojciulik** et al., *The impact of genetic polymorphism on course and severity of the SARS-CoV-2 infection and COVID-19 disease*, Przeglad Epidemiologiczny, doi:10.32394/pe/194862.

121. **Yip** et al., *The role of inflammatory gene polymorphisms in severe COVID-19: a review*, Virology Journal, doi:10.1186/s12985-024-02597-3.

122. **Serra-Llovich** et al., *Pharmacogenomic Study of SARS-CoV-2 Treatments: Identifying Polymorphisms Associated with Treatment Response in COVID-19 Patients*, Biomedicines, doi:10.3390/biomedicines13030553.

123. **İdikut** et al., *Association of Endothelial Nitric Oxide Synthase Polymorphisms with Clinical Severity in Patients with COVID-19*, Journal of Clinical Medicine, doi:10.3390/jcm14061931.

124. **Sokolenko** et al., *Antiviral Intervention of COVID-19: Linkage of Disease Severity with Genetic Markers FGB (rs1800790), NOS3 (rs2070744) and TMPRSS2 (rs12329760)*, Viruses, doi:10.3390/v17060792.

125. **Hakimi** et al., *HLA Polymorphisms and COVID-19 Susceptibility and Severity: Insights From an Iranian Patients Cohort*, Journal of Cellular and Molecular Medicine, doi:10.1111/jcmm.70570.

126. **Fajar** et al., *Insertion/deletion (I/D) polymorphisms of angiotensin-converting enzyme gene and their implications for susceptibility and severity of COVID-19: A systematic review and meta-analysis*, Narra J, doi:10.52225/narra.v4i3.727.

127. **Petrova** et al., *An Allele of the MTHFR one-carbon metabolism gene predicts severity of COVID-19*, medRxiv, doi:10.1101/2025.02.28.25323089.

128. **Jaurrieta-Largo** et al., *A Machine Learning Approach to Understanding the Genetic Role in COVID-19 Prognosis: The Influence of Gene Polymorphisms Related to Inflammation, Vitamin D, and ACE2*, International Journal of Molecular Sciences, doi:10.3390/ijms26167975.

129. **Cross** et al., *The evolutionary landscape of host immunity genes involved in respiratory and other immune-related diseases, and their association with severe COVID-19 outcomes*, medRxiv, doi:10.1101/2025.08.28.25334640.

130. **Karpenko** et al., *Genes Encoding Heat Shock Proteins Are Associated with Risk and Clinical Course of Severe COVID-19: A Pilot Study*, International Journal of Molecular Sciences, doi:10.3390/ijms26188967.

131. ***Covid Analysis (B)***, *Azelastine for COVID-19: real-time meta-analysis of 4 studies (Version 6)*, c19early.org/azlmeta.html.

132. ***Covid Analysis (C)***, *Cetylpyridinium Chloride reduces COVID-19 risk: real-time meta-analysis of 4 studies (Version 6)*, c19early.org/cpcmeta.html.

133. ***Covid Analysis (D)***, *Chlorhexidine reduces COVID-19 risk: real-time meta-analysis of 5 studies (Version 5)*, c19early.org/chxmeta.html.

134. ***Covid Analysis (E)***, *Chlorpheniramine reduces COVID-19 risk: real-time meta-analysis of 3 studies*, c19early.org/cpmmeta.html.

135. ***Covid Analysis (F)***, *Hydrogen Peroxide reduces COVID-19 risk: real-time meta-analysis of 8 studies (Version 5)*, c19early.org/hpmeta.html.

136. ***Covid Analysis (G)***, *Inhaled Heparin reduces COVID-19 risk: real-time meta-analysis of 3 studies*, c19early.org/iufhmeta.html.

137. **Covid Analysis (H)**, *Iota-carrageenan for COVID-19: real-time meta-analysis of 1 study (Version 3)*, c19early.org/gmeta.html.

138. **Covid Analysis (I)**, *NaCl reduces COVID-19 risk: real-time meta-analysis of 9 studies (Version 6)*, c19early.org/naclmeta.html.

139. **Covid Analysis (J)**, *Nitric Oxide reduces COVID-19 risk: real-time meta-analysis of 14 studies (Version 16)*, c19early.org/nometa.html.

140. **Covid Analysis (K)**, *Phthalocyanine reduces COVID-19 risk: real-time meta-analysis of 4 studies (Version 3)*, c19early.org/ptmeta.html.

141. **Covid Analysis (L)**, *Povidone-Iodine reduces COVID-19 risk: real-time meta-analysis of 21 studies (Version 40)*, c19early.org/pmeta.html.

142. **Brookes** et al., *Mouthwash Effects on the Oral Microbiome: Are They Good, Bad, or Balanced?*, International Dental Journal, doi:10.1016/j.identj.2023.08.010.

143. **Angjelova** et al., *Effects of Antiseptic Formulations on Oral Microbiota and Related Systemic Diseases: A Scoping Review*, Antibiotics, doi:10.3390/antibiotics14080815.

144. **Polyakova** et al., *The Effect of Oral Care Foams and a Spray on Salivary pH Changes after Exposure to Acidic Beverages in Young Adults*, Dentistry Journal, doi:10.3390/dj12040093.

145. **Meneguesso**, A., *Médica defende tratamento precoce da Covid-19*, www.youtube.com/watch?v=X5FCrIm_19U.

146. **Boulware**, D., *Comments regarding paper rejection*, twitter.com/boulware_dr/status/1311331372884205570.

147. **Meeus**, G., *Online Comment*, twitter.com/gertmeeus_MD/status/1386636373889781761.

148. **twitter.com**, twitter.com/KashPrime/status/1768487878454124914.

149. **Rothstein**, H., *Publication Bias in Meta-Analysis: Prevention, Assessment and Adjustments*, www.wiley.com/en-ae/Publication+Bias+in+Meta+Analysis:+Prevention,+Assessment+and+Adjustments-p-9780...

150. **Stanley** et al., *Meta-regression approximations to reduce publication selection bias*, Research Synthesis Methods, doi:10.1002/jrsm.1095.

151. **Rücker** et al., *Arcsine test for publication bias in meta-analyses with binary outcomes*, Statistics in Medicine, doi:10.1002/sim.2971.

152. **Peters**, J., *Comparison of Two Methods to Detect Publication Bias in Meta-analysis*, JAMA, doi:10.1001/jama.295.6.676.

153. **Moreno** et al., *Assessment of regression-based methods to adjust for publication bias through a comprehensive simulation study*, BMC Medical Research Methodology, doi:10.1186/1471-2288-9-2.

154. **Macaskill** et al., *A comparison of methods to detect publication bias in meta-analysis*, Statistics in Medicine, doi:10.1002/sim.698.

155. **Egger** et al., *Bias in meta-analysis detected by a simple, graphical test*, BMJ, doi:10.1136/bmj.315.7109.629.

156. **Harbord** et al., *A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints*, Statistics in Medicine, doi:10.1002/sim.2380.

157. **Donzelli**, A., *Neglected Effective Early Therapies against COVID-19: Focus on Functional Foods and Related Active Substances. A Review*, MDPI AG, doi:10.20944/preprints202312.1178.v1.

158. **Mir** et al., *Lysosomotropic properties of sodium bicarbonate and COVID-19*, Farmacia, doi:10.31925/farmacia.2020.5.1.

159. **Rashedi** et al., *Sodium Bicarbonate Nebulized Therapy in Patients with Confirmed COVID-19*, Advanced Pharmaceutical Bulletin, doi:10.34172/apb.2021.047.

160. **c19early.org (E)**, c19early.org/timeline.html.

161. **Kalayan** et al., *Safety and Efficacy of Nebulised Anti-Inflammatory Solution of Alkaline Hypertonic Ibuprofen (AHI) for Treatment of SARS-Cov-2 Infection: A Compassionate Study with a Comparator Arms*, European Journal of Respiratory Medicine, doi:10.31488/EJRM.132.

162. **repozitorij.mefst.unist.hr**, repozitorij.mefst.unist.hr/en/islandora/object/mefst%3A2314.

163. **sinomarin.com**, www.sinomarin.com/hypertonic-nasal-sprays-vials/.

164. **Mateja** et al., *The choice of viral load endpoint in early phase trials of COVID-19 treatments aiming to reduce 28-day hospitalization and/or death*, The Journal of Infectious Diseases, doi:10.1093/infdis/jiaf282.

165. **Deng**, H., *PyMeta, Python module for meta-analysis*, www.pymeta.com/.

166. **Zhang** et al., *What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes*, JAMA, 80:19, 1690, doi:10.1001/jama.280.19.1690.

167. **Altman**, D., *How to obtain the P value from a confidence interval*, BMJ, doi:10.1136/bmj.d2304.

168. **Altman (B)** et al., *How to obtain the confidence interval from a P value*, BMJ, doi:10.1136/bmj.d2090.

169. **Sweeting** et al., *What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data*, Statistics in Medicine, doi:10.1002/sim.1761.

170. **Altman (C)** et al., *Interaction revisited: the difference between two estimates*, BMJ, doi:10.1136/bmj.326.7382.219.

171. **Michelucci** et al., *SARS-CoV-2 ORF3a accessory protein is a water-permeable channel that induces lysosome swelling*, Communications Biology, doi:10.1038/s42003-024-07442-5.

172. **Ghosh** et al., *β-Coronaviruses Use Lysosomes for Egress Instead of the Biosynthetic Secretory Pathway*, Cell, doi:10.1016/j.cell.2020.10.039.

173. **Kamga Kapchoup** et al., *In vitro effect of hydroxychloroquine on pluripotent stem cells and their cardiomyocytes derivatives*, Frontiers in Pharmacology, doi:10.3389/fphar.2023.1128382.

174. **Bobrowski** et al., *Synergistic and Antagonistic Drug Combinations against SARS-CoV-2*, Molecular Therapy, doi:10.1016/j.ymthe.2020.12.016.

175. **Peters (B)** et al., *Outcomes of Persons With COVID-19 in Hospitals With and Without Standard Treatment With (Hydroxy)chloroquine*, Clinical Microbiology and Infection, doi:10.1016/j.cmi.2020.10.004.

176. **Mahévas** et al., *Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data*, BMJ 2020, doi:10.1136/bmj.m1844.

177. **Minozzi** et al., *The revised Cochrane risk of bias tool for randomized trials (RoB 2) showed low interrater reliability and challenges in its application*, Journal of Clinical Epidemiology, doi:10.1016/j.jclinepi.2020.06.015.

178. **Popp** et al., *Ivermectin for preventing and treating COVID-19*, Cochrane Database of Systematic Reviews, doi:10.1002/14651858.CD015017.pub3.

179. **Reis** et al., *Effect of Early Treatment with Ivermectin among Patients with Covid-19*, New England Journal of Medicine, doi:10.1056/NEJMoa2115869.

180. **Axfors** et al., *Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials*, Nature, doi:10.1038/s41467-021-22446-z.

181. **Horby** et al., *Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled trial*, NEJM, doi:10.1056/NEJMoa2022926.

182. **Hempenius** et al., *Bias in observational studies on the effectiveness of in hospital use of hydroxychloroquine in COVID-19*, Pharmacoepidemiology and Drug Safety, doi:10.1002/pds.5632.

183. **de Gabory** et al., *Seawater nasal wash to reduce symptom duration and viral load in COVID-19 and upper respiratory tract infections: a randomized controlled multicenter trial*, European Archives of Oto-Rhino-Laryngology, doi:10.1007/s00405-024-08518-y.

184. **Yilmaz** et al., *Effects of hypertonic alkaline nasal irrigation on COVID-19*, Laryngoscope Investigative Otolaryngology, doi:10.1002/lio2.686.

185. **Calonico** et al., *Causal Inference During a Pandemic: Evidence on the Effectiveness of Nebulized Ibuprofen as an Unproven Treatment for COVID-19 in Argentina*, National Bureau of Economic Research, doi:10.3386/w30084.

186. **Delić** et al., *Effects of Different Inhalation Therapy on Ventilator-Associated Pneumonia in Ventilated COVID-19 Patients: A Randomized Controlled Trial*, Microorganisms, doi:10.3390/microorganisms10061118.

187. **El-Badrawy** et al., *Efficacy and safety of nebulized Sodium Bicarbonate in adults with COVID-19 (SODIC): a randomized, single center, double-blinded, controlled trial*, Current Therapeutic Research, doi:10.1016/j.curtheres.2025.100801.

188. **El-Badrawy (B)** et al., *Role of Sodium Bicarbonate as Adjuvant Treatment of Nonsevere Computed Tomography-identified COVID-19 Pneumonia: A Preliminary Report*, Indian Journal of Respiratory Care, doi:10.4103/ijrc.ijrc_48_21.

189. **Lumlertgul** et al., *The effects of urine alkalinization on kidney function in critically ill patients with COVID-19: a proof-of-concept randomized clinical trial*, Intensive Care Medicine Experimental, doi:10.1186/s40635-025-00739-7.

190. **Mody**, K., *Effect of 8.4% Soda-Bicarbonate Steam Inhalation on the Course of Disease in Mild to Moderate Cases of Covid-19*, Acta Scientific Orthopaedics, 4:4, actascientific.com/ASOR/ASOR-04-0290.php.

191. **Pantazopoulos** et al., *A Hypertonic Seawater Nasal Irrigation Solution Containing Algal and Herbal Natural Ingredients Reduces Viral Load and SARS-CoV-2 Detection Time in the Nasal Cavity*, Journal of Personalized Medicine, doi:10.3390/jpm13071093.

192. **Salva** et al., *Reversal of SARS-CoV2-Induced Hypoxia by Nebulized Sodium Ibuprofenate in a Compassionate Use Program*, Infectious Diseases and Therapy, doi:10.1007/s40121-021-00527-2.

193. **Soares** et al., *Preliminary observation of the use of sodium bicarbonate solution as an adjunct in the treatment of coronavirus 2019 disease (COVID-19): prognosis improvement in patients requiring intensive care*, Brazilian Journal of Development, doi:10.34117/bjdv7n12-039.

194. **Wang (B)** et al., *Efficacy of nasal irrigation and oral rinse with sodium bicarbonate solution on virus clearance for COVID-19 patients*, Frontiers in Public Health, doi:10.3389/fpubh.2023.1145669.

195. **Karami** et al., *A Comparison of the Effects of Chlorhexidine and Sodium Bicarbonate Mouthwashes on COVID-19–Related Symptoms*, Iranian Journal of Nursing and Midwifery Research, doi:10.4103/ijnmr.ijnmr_38_23.

196. **Hayward** et al., *Ivermectin for COVID-19 in adults in the community (PRINCIPLE): an open, randomised, controlled, adaptive platform trial of short- and longer-term outcomes*, Journal of Infection, doi:10.1016/j.jinf.2024.106130.

197. ***ibc2024.org***, www.ibc2024.org/viewdocument/sander-greenland-ibc-2024-president.

198. ***c19early.org (F)***, c19early.org/phmeta.html#media.

199. ***c19early.org (G)***, c19early.org/adoption.html.